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Abstracts of Invited Papers
The epidemiology of lung cancer in the West of Scotland -
Pointers for the future?
C.R. Gillis & D.J. Hole
West ofScotland Cancer Surveillance Unit, Ruchill Hospital,
Glasgow, UK.
The West of Scotland has some of the highest rates of both
lung cancer and heart disease recorded. If an epidemiological
study of cigarette smoking and lung cancer showed dif-
ferences from those previously reported it might point to
new approaches. A case-control study of 656 males with
twice that number of non-smoking related controls has
shown a linear increase in the relative risk of heart disease,
but little increase in relative risk of lung cancer above an
average exposure of 15-24 cigarettes per day (the cell type
determined in 90% of cases studied). Despite the reduction
in tar content since levels were first measured, medium tar
cigarettes still conferred high relative risk if more than 15
cigarettes per day were smoked. None of these findings are
explained by smoking practices peculiar to the West of
Scotland. Smokers returned to the risk of lung cancer in
non-smokers following 20 years of ex-smoking.
A cohort of 15,399 apparently healthy males and females
aged 45-64 was examined between 1972 and 1976 by multi-
phasic screening for cardiovascular risk including measure-
ment of blood pressure, ECG, serum cholesterol and FEVI.
These were entered into the cancer registry in 1972. By
December, 1986, 2711 of these have died and the cohort
mortality for lung cancer shows, for equal amounts smoked,
that the West of Scotland population is at more than twice
the absolute risk of lung cancer than any of the cohort
studies in the literature.
Also an increasing dose response relationship for lung
cancer was found comparing controls, passive smokers
(relative risk =2.4), those who smoked and smokers who
lived in households where at least one other member of the
household smoked.
The rates of lung cancer in those now living in green field
sites in the new towns around Glasgow but who lived within
the City of Glasgow in the 1950s were only slightly lower
than in Glasgow itself. So the additional risk of lung cancer
from either passive smoking or atmospheric pollution does
not account for the West of Scotland excess which continues
to be observed compared to other Scottish cities.
Serum cholesterol readings from those apparently healthy
individuals measured at least 4 years prior to the diagnosis
of lung cancer or any other cancer show that high serum
cholesterol levels were associated with low rates of lung
cancer, contrary to many published findings.
This and the surprising nature of the dose-response
relationship allow speculation about the existence of a
genetic component in the aetiology.
An epidemiological study has been carried out of know-
ledge and opinion in Glasgow, Manchester and Leeds about
symptoms and signs that may mean cancer. While know-
ledge improved with increased inputs of education, education
itself appeared less important than other variables (age, sex,
family experience of cancer, social class) in determining
knowledge.
Education on lung cancer prevention in schools
A. Charlton
Cancer Research Campaign Education and Child Studies
Research Group, University ofManchester, UK.
Probably the least effective way to prevent lung cancer is to
teach about lung cancer prevention. When the link between
lung cancer and smoking became clear, it was generally
assumed that if people were familiarised with this association
they would not smoke.
In a study by the author in 1979, children who smoked
were significantly more likely than nonsmokers, to state that
smoking can cause lung cancer. Bewley and her colleagues
showed that although children could name diseases as-
sociated with smoking they did not understand the meaning.
Diseases which might strike at the age of 40 or over are
much too distant to have any meaning for children. Some
children enjoy the added excitement of risk. Others are made
very anxious if their parents smoke and lectures about health
risks can be very boring.
It is nevertheless imperative that something should be
done to prevent children from smoking, as Doll and Peto
have shown that the risk of lung cancer increases the earlier
smoking is started.
Regular two-yearly surveys carried out by the OPCS now
show the prevalence of smoking among children. Nearly
30% of young people are regular smokers at school-leaving
age. The prevalence is higher among the less academically
inclined. A large CRC-funded study showed that among 16
to 18-year-olds at vocational colleges the prevalence of
regular smoking was 31% whilst in the same age group in
the sixth forms it was 12%. The same survey showed that
children whose parents smoke are nearly twice as likely to be
smokers; whilst parents' approval is associated with a seven
times increased rate. Only 2% of children would smoke if
they thought their best friend was not in agreement.
Young smokers are likely to attend more discos more
often than the nonsmokers; to attend gigs more often; to
drink alcohol more often. Young smokers are already more
likely than nonsmokers to express positive views about
smoking e.g. that it calms the nerves, keeps the weight down,
gives confidence. Perhaps this is related to advertisement-
awareness because smokers were significantly more likely
than nonsmokers to have a favourite cigarette advertisement.
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The peak age for trying a first cigarette is 9 or 10 years.
At 12 or 13 regular smoking becomes established and at 15
or 16 the desire to stop smoking increases.
Smoking control education needs to take place at the
critical times; it needs to take into account the children at
high risk of becoming smokers and focus on overcoming
lifestyle problems.
Above all it must seem relevant to them. A recent CRC
study showed that teenage smokers were significantly less
likely than nonsmokers to be interested in sport. Health
education should take into account where those who are
smokers want to be; in the discos, in the rock concerts, in
the pubs. Health must be compatible with their own lifestyle
and background.
Classification of lung cancer
M.S. Dunnill and K.C. Gatter
Histopathology Department, John Radcliffe Hospital, Oxford,
OX3 9DU, UK.
For the past twenty years pathologists have classified lung
cancer according to the system devised by WHO Kreybeg et
al. (eds) Histological typing of lung tumours (WHO, 1967;
Amer. J. Clin. Pathol. 77, 123, 1982). This relied entirely on
light microscopical appearances and was detailed, complex
and took little account of histogenesis. Recent investigations
(Dunnill & Gatter, Histopathology, 10, 461, 1986) using
electron microscopy and modern immunocytochemistry have
called into question the validity of this classification and
have favoured the concept, originally put forward by Willis
(Inm Pathology of tumours, 3rd edn., Butterworths, London,
1960, p. 368), that lung cancer is a single entity, albeit with
one cell type often dominating the histological appearance in
any given tumour.
To date a total of 161 lung tumours removed at lobec-
tomy or pneumonectomy have been investigated. Portions of
tumour tissue taken immediately after removal were (i) snap
frozen in liquid nitrogen for immunocytochemistry, (ii) fixed
in buffered glutaraldehyde for electron microscopy and (iii)
placed in buffered formol saline for processing for light
microscopy. Frozen sections were examined, using a three
stage immunoperoxidase procedure or the APAAP immuno-
alkaline phosphatase technique, with monoclonal antibodies
against cytokeratins of varying molecular weight, neurally
related antigens, carcinoembryonic antigen, vimentin and
desmin. Material submitted for electron microscopy was
scrutinised for the presence of dense core granules, tonofila-
ments, mucous secretory vesicles or for an acinar arrange-
ment to the tumour cells. Paraffin sections were stained for
mucus using the alcian blue/PAS method and for silver
positive granules employing the Grimelius method.
Tumours were classified by light microscopy into one of
four categories, viz. squamous carcinoma, small cell car-
cinoma, carcinoids or adenocarcinoma. Immunocytochemical
investigation of these tumours showed that those with a clear
differentiation towards one of the categories mentioned
above tended to have a characteristic immunocytochemical
profile. Yet there was considerable cross reactivity. Thus
tumours classed as squamous carcinomas often exhibited
focal areas which reacted with the antineural antibody
UJ13A which typically stains small cell carcinomas. Similarly
small cell carcinomas often contained elements which stained
positively for high molecular weight keratins. Another find-
ing of interest was that many tumours showed inappropriate
co-expression of intermediate filament proteins. Thus some
carcinomas reacted with antivimentin or antidesmin anti-
bodies, a feature that is normally found only in connective
tissue or muscle. This cellular heterogeneity was further
confirmed by examination of ultrastructure and by mucous
histochemistry. Many tumours which appeared to be of
squamous origin on light microscopy were found to contain
dense core granules or mucus-secreting elements.
It is thus apparent that many, perhaps the majority, of
lung tumours do not differentiate along one pure cell line.
This implies that rigid allocation of lung cancers into WHO
categories gives a misleading idea with respect to histogenesis
of these tumours. Further support for this comes firstly from
biochemical investigation of lung cancers which has shown
that many non-small cell cancers contain markers that were
once thought to be found only in small cell tumours.
Secondly, measurements of cell and nuclear size in so-called
small cell tumours has revealed that the term small cell is
itself spurious as there is a continuous distribution of cell
size from small to large cell tumours.
Thirdly, there is strong epidemiological evidence linking
small cell carcinoma with other forms of lung cancer in that
all are related to smoking and to uranium exposure.
These findings are most in keeping with the concept that
the carcinogenic stimulus affects a pleuripotential basal or
reserve cell which then proliferates along one or more
pathways. This view would support that of Yesner and
Carter (Clin. Chest Med. 3, 257, 1982) who stated that 'all
lung cancers are part of a spectrum of differentiation.'
Historical review
C. Ogilvie
Royal Liverpool Hospital, Prescot Street, Liverpool, UK.
On the occasion of the British Lung Cancer Conference, it
seemed appropriate to view the history of lung cancer
through the eyes of readers of British medical journals.
Three journals were selected: the Quarterly Journal of
Medicine (a journal for general physicians), Thorax (a jour-
nal for chest physicians and surgeons) and the British
Journal ofCancer (a journal for oncologists). During the first
80 years of the life of the Quarterly Journal of Medicine
(1907-1986) and the first 30 years in the life of the other two
journals (1947-1977), a total of 222 papers on lung cancer
were published. Only 9 of these appeared in the Quarterly
Journal of Medicine and less than 5% in the other two
journals dealt with this commonest of all cancers. In the
British Journal of Cancer, there were twice as many papers
on colon cancer and three times as many on breast cancer.
This relative disinterest in lung cancer may be due in part to
the fact that, unlike other common cancers, cancer of the
lung is in most cases self-inflicted and preventable, but
incurable even when early diagnosis is achieved.
Dividing the papers into 5 broad categories, there were 95
on aetiology, 34 on epidemiology, 30 on histocytology, 33 on
clinical aspects and 18 on treatment.
The majority of the papers on aetiology related to the
analysis of cigarette and urban smoke for carcinogens and
the study in small laboratory animals of lung tumours
induced by smoke constituents.
Epidemiological studies described the possible relation of
lung cancer to smoking, occupation, sex or domicile (urban
or rural) but smoking habits were not always taken into
account when the effects of other variables were examined.
Two thirds of papers in this category were accounts of lung
cancer patterns in overseas countries.
Of the 30 papers under the heading of histocytology, 20
dealt with differences in the clinical features, smoking habits,
prognosis or treatment of patients with different cell types of
lung cancer. Sputum cytology was the subject for most of
the remainder.
More than half the 33 clinical papers described metastatic
spread of the disease, 10 being accounts of techniques for the
recognition of mediastinal involvement. There was only one
paper on early diagnosis and none on any aspect of
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There were 12 papers in Thorax on the surgical treatment
of lung cancer but only six of the 222 papers in the three
journals dealt with medical management. There were no
papers on either the prevention or palliation of the disease.
It is concluded that an occasional audit of papers pub-
lished in medical journals may draw attention to areas of
neglect, bearing in mind that research endeavour is not
necessarily geared to clinical need. It would seem that in the
three journals examined during the period under review, lung
cancer was itself an area of comparative neglect, especially
with regard to early diagnosis, prevention and palliation.
Model systems for lung cancer
P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge, UK.
There is clearly no one model system which can contain all
the elements which make up human lung cancer. The
appropriate model for any particular study will need to
include the essential determinants which provide the bio-
logical basis of the phenomenon under investigation. In
addition to the neoplastic cell population, a varying degree
of differentiation, and a stromal component (cellular and
extracellular) will define a tumour mass. The reaction of the
host to the presence of the tumour will also, in many cases,
influence the behaviour of the tumour cells.
Animals lung tumours have made only a small contri-
bution to date with regard to our understanding of the
biology of human lung cancer. Tumours produced in mice
and rats by inhalation of carcinogens (including tobacco
smoke) are not generally of the same histological types as
the common human tumours. More recently, however,
animal models bearing a closer histological relationship to
the common types of lung cancer have been developed.
Much of our current data have been obtained by the use of
cell lines or xenograft tumours grown from human clinical
material. There is no doubt that production of cell lines or
the establismment xenografts entail a high degree of selective
pressure and that the final product represents the progeny of
only a small proportion of the cells present in the original
sample. Under appropriate conditions, however, both cell
lines and xenografts retain the chemo- and radiosensitivity
characteristics of the original tumour type. Cell lines also
maintain many of the cytological, ultra-structural and neuro-
endocrine properties of the original material. One must be
aware of the possibility, however, that phenomena such as
oncogene amplification may reflect events occurring in vitro
during establishment of the cell line and not in the tumour
in situ.
In addition to growth as monolayers or floating ag-
gregates of cells, cell lines may also be grown as multicellular
tumour spheroids. These three-dimensional balls of cells (up
to I mm in diameter) may be useful for studies of inter-
cellular communication, factors determining the onset of cell
death, and cytotoxic drug penetration.
The problem of acquired drug resistance in small cell lung
cancer has prompted several groups to derive drug-resistant
cell lines. In the absence of definitive evidence as to the
nature of drug resistance as seen in the clinic, it is difficult to
assess the relevance of such models. However, some of the
protein changes seen in the cell lines do correspond to
changes which are believed to have clinical significance in
other tumour types. These model systems may help in the
development of strategies for dealing with drug-resistant
disease, such as identification of drug analogues with greater
retention of activity in resistant disease and additional
chemicals which can act as 'resistance modifiers'.
Markers in lung cancer
J.G. Reeve
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge, UK.
The development of sensitive radioimmunoassays for en-
zymes and peptide hormones, the production of monoclonal
antibodies to cell surface determinants and investigations
into the molecular genetics of lung cancer have generated a
wealth of data regarding the expression of endocrine mar-
kers, membrane antigens, cytogenetic markers and the ampli-
fication/expression of oncogenes in lung tumour cell lines
and patient material. It is now clear from such studies that a
considerable overlap exists between SCLC and NSCLC
particularly with respect to the expression of endocrine-
related markers and cell surface protein phenotype, suggest-
ing perhaps a common cellular origin for all types of lung
cancer. Importantly, the expression of endocrine properties
by some but not all SCLC and NSCLC tumours has
prompted clinical trials in which, in addition to routine
histology, lung tumours are classified according to their
endocrine status to determine whether there is a correlation
between the expression of endocrine properties and response
to therapy and survival.
Whilst the presence or absence of a given biochemical
marker may be of dubious value in the differential diagnosis
of lung cancer, certain biomarkers, e.g. neuron specific
enolase and calcitonin, may be useful in monitoring therapy,
particularly in patients with SCLC and in the diagnosis of
CNS metastases. However, despite a voluminous literature, a
well defined role for markers in decisions on therapy has not
yet been presented. There is, for example, no single marker
for which elevated levels can be detected in all patients; some
markers, e.g. bombesin, cannot be detected in serum or
plasma; the absolute level of a marker does not indicate
tumour burden in the individual patient; marker levels do
not necessarily increase upon relapse and if they do rise, this
does not always indicate relapse. Furthermore, few studies
indicate that measurements of markers might improve on the
prognostic evaluation as normally performed with staging
and performance status.
The search for reliable tumour markers has prompted
many groups to develop monoclonal antibodies (MoAbs) to
membrane determinants. Although many MoAbs have been
generated, their widespread use has been limited by the lack
of specificity of individual antibodies and by the problem of
antigenic heterogeneity. However, some may be of value in
the differential diagnosis of lung cancer, in monitoring
therapy, in the detection of metastases and in the in vitro
elimination of tumour cells from contaminated marrow prior
to autologous reinfusion.
While considerable heterogeneity exists within a given
tumour with respect to many biochemical markers, deletion
of chromosome 3p has been detected with remarkable consis-
tency in SCLC using specific DNA probes. Further studies
are required in order to confirm whether this deletion also
occurs at high frequency in NSCLC tumours and whether a
recessive tumour suppressor gene may be involved in the
development of lung cancer in general.
The identification of selected biomarkers, e.g. bombesin,
as autocrine growth factors has led to speculation that
interacting neuroendocrine signals are involved in SCLC
growth control. A monoclonal antibody to bombesin has
been produced which inhibits the growth of SCLC both in
vitro and in xenografts, and is now entering a phase I clinical
trial, providing one example of how disruption of signal
transduction may represent a new form of endocrine therapy
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Antigens of small cell lung cancer (SCLC)
A Report on the First International Workshop on Antigens
in Small Cell Lung Cancer
R.L. Souhami
Department ofOncology, University College and Middlesex
School ofMedicine, University Street, London, WC2E 6AU,
UK.
By 1986 over 100 monoclonal antibodies reacting with SCLC
had been described. Some of these showed reactivity with
neural as well as epithelial tissues and others showed only
epithelial reactivity. Because of the wide range of techniques
and target tissues which had been employed in the definition
of reactivity in different laboratories, it was difficult to
determine whether the same or related antigens were being
defined by antibodies from different laboratories.
Following the success of the Leucocyte Antigen Work-
shops we proposed an International Workshop on SCLC
Antigens, the intention being to define clusters of antibodies
recognising closely related antigenic determinants. Seventeen
laboratories submitted 52 monoclonal antibodies (MoAbs)
and 20 laboratories returned data from FACS, immunocyto-
chemistry and immunohistochemistry experiments. All ex-
periments were performed on MoAbs secretly coded by the
central registry. The cluster analysis was made from 20,460
results.
Six clusters were defined. Cluster 1 consisted of 9 reagents
which recognised an SCLC antigen which was also present
on nerve, neuroblastoma, carcinoid, renal carcinoma, mela-
noma, thyroid epithelium, Leydig cells and erythrocytes. It is
lost in fixation of tissue and is not well expressed on other
forms of lung cancer.
The antigen appears to be a glycoprotein of mol. wt 160kd.
34MoAbs were designated 1-Associated (1-A) because of a
similar but not identical reactivity. Two worked on fixed
tissue.
Cluster 2 consisted of 4MoAbs recognising a glycoprotein
antigen of mol. wt29-40kd. It reacts with SCLC, most other
carcinomas, but weakly with melanoma.
Cluster 3 consisted of 2MoAbs which recognised cells in
cycle. They are probably unrelated molecules and for this
reason the cluster was designated as a 'workshop' cluster -
W3.
Cluster W4 contained 2MoAbs which reacted both with
SCLC neuroblastoma and normal nerve as well as most
carcinomas. The nature and mol. wt of the antigen is
unknown.
Cluster 5 was made up of 3 MoAbs which reacted with
SCLC, neuroblastoma melanoma and some carcinomas. It
works well in fixed tissue. The antigen may be a glycoprotein
mol. wt95-139kd. One other antibody was designated as
5-A.
Cluster W6 was composed of 2 reagents which recognised
SCLC and most epithelia. The antigen may be a sugar
hapten on a glycoprotein or glycolipid.
The workshop showed that the cluster analysis could be
used on data from immunohistochemistry, and indicates that
a systematic classification of antigens on cancer cells is
possible. Further workshops are planned, and we hope that
the findings of the SCLC workshop may stimulate similar
endeavours in other tumours.
Clinical relevance of lung cancer biology
D.N. Carney
Mater Hospital, Dublin 7, Ireland.
While many factors such as performance status or disease
extent influence the response to therapy and survival of
patients with SCLC, it is possible that certain biological
properties inherent to the tumour cells themselves may also
be of prognostic importance. Such properties including the
expression of endocrine properties, drug or radiation resist-
ant genes or cellular oncogenes may account for the ob-
served variability in clinical responses to cytotoxics. In
studies of large panels of established cell lines of both SCLC
and NSCLC, significant heterogeneity in the expression of a
range of biomarkers has been noted. Moreover, the overlap
in the expression of certain properties by both small cell and
non small cell suggests that in some instances a common
stem cell may exist for all cell types of lung cancer. Using a
chemically defined medium (HITES), with or without serum
supplementation, cell lines of SCLC can now be established
from 70-75% of all clinical specimens containing tumour
cells. The majority of SCLC cell lines grow as floating
aggregates of tight-to-loosely packed cells, frequently demon-
strating central necrosis. DNA content analysis by flow
cytometry of both fresh specimens and cell lines of SCLC
has demonstrated considerable heterogeneity. Discrete
aneuploid lines are present in up to 85% of all specimens
with 10-20% having multiple stem lines. Thus far no
correlation has been noted between the degree of aneuploidy
and response to therapy and survival in these patients with
SCLC. Cytogenetic studies have also confirmed the
heterogeneity of SCLC. A specific cytogenetic abnormality
involving a portion or all of the short arm of chromosome 3
has been detected in this tumour. In addition, double minute
chromosomes and/or homogenous staining regions (HSR)
have also been observed. The latter may represent amplifi-
cation of drug resistant genes or oncogenes and thus may be
associated with the more malignant behaviour of the tumour
tvpc.
When a large panel of cell lines established from patients
with SCLC was examined with respect to a variety of
biomarkers including L-dopa decarboxylase (DDC), bom-
besin (BN), neuron specific enolase (NSE) and the BB
isozyme of creatine kinase (CK-BB) the cell lines could be
subdivided into two major groups, viz., classic and variant
cell lines. Classic SCLC cell lines grow as tight aggregates of
cells and have elevated levels of all 4 biomarkers. In contrast
variant cell lines have selective loss of both DDC and BN
but continue to express elevated levels of CK-BB and NSE.
This is in contrast to NSCLC cell lines in which all 4
biomarkers are usually absent. In addition to their lack of
expression of DDC and BN, variant cell lines could be
differentiated from classic lines by their gross morphology in
culture, by electron microscopy examination and by their
growth properties in vitro. Variant cell lines have a more
aggressive growth behaviour, are radioresistant and exhibit
20-70 fold amplification of the c-myc oncogene. Indirect
evidence suggests that patients with the variant phenotype
have a poorer response to chemotherapy and a shorter
survival than patients with classic SCLC. Further studies of
oncogene expression in both fresh specimens and cell lines of
SCLC have revealed amplification of myc-related oncogenes,
viz., N-myc and L-myc, in a large proportion of specimens.
These data, coupled with the c-myc data, suggest that
amplification and/or expression of myc-related oncogenes
may be important in the establishment, maintenance or
malignant behaviour of SCLC.
Finally in a small fraction of cell lines derived from
patients with small cell, morphological and electron micro-
scopy studies have revealed features of SCLC, adenocarci-
noma and squamous cell carcinoma in individual cells. These
features are clonally retained and thus suggest the possibility
of a common stem cell for all types of lung cancer. In
addition it is now clear that up to 20% of NSCLC, in
particular adenocarcinoma, have biomarkers typical of
SCLC lines suggesting that all lung cancers (NSCLC and
SCLC) can be subdivided into those with endocrine pro-
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Future clinical trials should evaluate the prognostic value of
these biomarkers in predicting clinical response and survival
after cytotoxic therapy.
The assessment of the lung cancer patient
S.G. Spiro
Brompton Hospital, London, SW3 6HP, UK.
Assuming the average size of a non-small cell lung cancer
(NSCLC) tumour is 3-4cm diam. on the chest X-ray at
diagnosis, its natural history to death comprises 3-5 volume
doubling times i.e. 9-18 months dependent on its growth
rate. The very late presentation of the tumour explains why
metastatic disease often co-exists at diagnosis and why the
overall 5 year survival figures, including patients undergoing
resection is only 5-8%. Nevertheless surgery offers the only
chance of cure whilst radiotherapy and chemotherapy will
make very little impact on survival.
The important factors to consider in selecting which
patients should undergo further assessment and staging of
their tumours include:
(i) Age - with its increasing peri-operative mortality and
morbidity in those over 70 years. However lung
cancer in the elderly is as aggressive as in younger
subjects with a 93% mortality untreated at 1 year-
far in excess of the life expectancy of 70 and 80 year
old subjects. Recent studies claim peri-operative
mortality has been reduced to 5-7%, and the 5 year
survival in patients more than 70 yr. can reach 35%.
(ii) General health - this assessment is less precise but the
physical and mental status of the sufferer needs
careful assessment with particular stress on recent
coronary artery disease, and evidence of peripheral
and cerebrovascular disease - factors known to ad-
versely affect post operative mortality.
(ii) Social support - particularly in elderly patients may
prove the major factor in deciding for or against
surgery.
(iv) Radiology - the chest radiograph is the most import-
ant investigation in making the diagnosis of lung
cancer, and will give useful information as to the
extent of the disease. In diagnosing the presence of a
tumour, difficulties often arise in identifying changes
in hilar density, shadowing behind the heart, noting
lesions in the central airways, and detecting under-
perfusion of a lobe or lung due to larger airways
obstruction or direct invasion of the pulmonary ar-
tery. Pancoast tumours are often missed until rib
erosion occurs despite long histories of arm or shoul-
der pain.
(v) The prediction of post-operative lung function re-
mains a difficult area - particularly when the tumour
is within the lung not obviously causing airway occlu-
sion but its effect on gas exchange, notably perfusion,
uncertain. If the tumour is not central most would
exclude from surgery the patients with an FEV1 of
<1.5 litres unless lobectomy or segmentectomy was
certain (which it often is not). However pre-operative
ventilation perfusion scanning to determine the per-
centage ventilation for the lung to be resected corre-
lates highly with changes in FEV1, and the gas
transfer coefficient post-operatively also offers reason-
ably precise prediction of the post-operative lung
function. These assessments should become routine.
(vi) Bronchoscopy - will both confirm the diagnosis and
provide important information relevant to operability
such as site of tumour and evidence of extra bronchial
node involvement.
Radionuclide imaging of lung tumours
A.C. Perkins
Department ofMedical Physics, University Hospital, Queen's
Medical Centre, Nottingham, UK.
The incidence of primary lung cancer continues to rise yet
no significant improvement in patient survival has resulted,
despite the introduction of more vigorous screening pro-
cedures. Although detection and staging is now easier using
X-ray CT approximately 50% of patients have distant
metastases at the time of diagnosis.
In the past, radionuclide imaging has played only a minor
role in the detection of lung tumours and ventilation and
perfusion imaging have largely been reserved for the detec-
tion of pulmonary embolism. The main limitation of nuclear
medicine in clinical oncology has been the lack of tumour-
seeking radiopharmaceuticals. Agents such as In-111-indium
chloride, In-l1-bleomycin and Ga-67-citrate have been ad-
vocated with variable results. The most commonly adopted
agent, Ga-67-citrate, has been reported to have detection
sensitivities between 65 and 95% but uptake in abscess and
inflammation has resulted in low specificity.
The more recent introduction of monoclonal antibodies
offers potential for both the diagnosis and therapy of
malignant disease: however, relatively few antibodies have
been shown to localise in primary lung tumours. The tech-
nique of immunoscintigraphy using iodine and indium-
labelled antibodies has mainly been carried out using anti-
bodies raised against CEA although reported patient num-
bers have been small.
Studies carried out in Nottingham of 21 patients with
primary lung carcinoma have shown that the monoclonal
antibody 791T/36 (originally raised against a human osteo-
sarcoma) will localise to an extent sufficient for imaging
primary squamous cell and small cell lung tumours. In
particular, superior detection was obtained with In-111-
labelled antibody and emission tomography using a rotating
gamma camera, where lung metastases smaller than 1 cm in
diameter have been detected. These studies have provided
preliminary information prior to therapeutic trials with drug-
antibody conjugates.
The future development of antibodies specific for lung
tumours coupled with advances in equipment design would
appear promising.
The role of surgery in non-small cell lung cancer
D.C.T. Watson
East Birmingham Hospital, Birmingham, B9 SST, UK.
Surgery is the only form of treatment that offers a reason-
able chance of cure but the results depend upon disease
extent when the patient presents. The cell type is less
important as a predictor of survival but for mediastinal node
involvement squamous carcinoma is more favourable in the
operable case (Mountain, Ann. Thorac. Surg., 33, 365, 1977;
Naruke et al., J. Thorac. Cardiovasc. Surg., 76, 832, 1978).
Five year survival in Stage I disease is over 60% (Cooper et
al., Chest, 87, 289, 1985) but this is almost halved once hilar
or mediastinal glands are involved.
In patients with N1 disease attempts to improve survival
figures using adjuvant therapy are variable (Martini et al., J.
Thorac. Cardiovasc Surg., 86, 646, 1983; Ferguson et al., J.
Thorac. Cardiovasc Surg., 91, 344, 1986). Post-operative
combination therapy (Newman et al., J. Thorac. Cardiovasc
Surg., 86, 180, 1983) showed some advantage over surgery
alone but the surgical results were poor compared with many
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et al. (Cancer Chemother. Rep., 4, 63, 1973) who demon-
strated residual disease following curative resection. There
are few large studies of adjuvant therapy in patients with N2
disease and the current MRC and EORTC trials hope to
address the problem. Many series have shown a 5 year
survival of 29% following surgery alone. The United States
National Lung Cancer Study Group have demonstrated
improved survival in Stage II and III disease in patients with
adenocarcinoma or undifferentiated large cell carcinoma
receiving post-operative chemotherapy, but no advantage
was demonstrated for those with squamous carcinoma
receiving radiotherapy, but there was a marked reduction in
the incidence of local recurrence. Patients with ipsilateral
mediastinal node involvement and otherwise operable disease
should still be offered surgery (Pearson et al., J. Thorac.
Cardiovasc. Surg., 83, 1, 1982) until a better alternative can
be found.
Paulson's technique for superior sulcus tumours (Paulson
et al., J. Thorac. Cardiovasc Surg., 44, 281, 1962) fails in
many patients with extensive disease but Ellis (Shahian et al.,
Ann. Thorac. Surg., 43, 32, 1987) has shown a 5 year
survival of 56% in patients receiving pre- and post-operative
irradiation in patients with extensive disease.
Tumours invading the chest wall directly without
mediastinal disease should be offered surgery since 30% will
survive 5 years.
In the small group of patients with a solitary brain
metastasis from bronchial carcinoma craniotomy should be
considered since 2 studies (Patchell et al., Neurology, 36, 447,
1986; Magilligan et al., Ann. Thorac. Surg., 42, 360, 1986)
have shown marked survival advantages for patients treated
surgically.
Twenty percent of long term survivors following resection
of Stage I carcinoma and 38% of survivors of resection for a
radiologically occult carcinoma will develop a second solitary
lung cancer. After thorough staging they should be consi-
dered for surgery as 70% will survive one year and 27% 3
years.
Improvement in post-operative survival will only be
achieved by earlier diagnosis or better adjuvant therapy.
Radiotherapy in non-small cell lung cancer
S. Dische
Mount Vernon Hospital, Northwood, Middlesex, UK.
Radiotherapy is a valuable method for palliation of symp-
toms due to the primary tumour and to metastasis in
carcinoma of the bronchus. When patients with disease
apparently confined to the chest are treated with the object-
ive of long term control 40% may survive a year and 15%
two years, with an occasional patient living 5 years or more;
nearly all the patients succumb to the primary tumour and/
or metastasis.
In the UK most radiotherapists feel that distant metastasis
determines survival and a radiation dose sufficient to achieve
full eradication of tumour is rarely attempted in bronchial
carcinoma for it is felt that a long and intensive course to
the primary site is not justified.
We have reported that in a series of 61 patients with
apparently localised disease treated by radiotherapy, 44
(72%) died due to uncontrolled local tumour, despite the
treatment given and that 24 (39%) showed no evidence of
metastasis at death (Saunders et al., Int. J. Radiat. Oncol.
Riot. Phys., 10, 499, 1984). An effort to improve radio-
therapy so as to increase local tumour control seems
justified.
Attention has been given to the resistance of hypoxic
tumour cells, the tumour cell kinetics of bronchial car-
cinoma, improvement in planning using CT scanning and so
to the individualisation of treatment for each case.
Hypoxic cell sensitisers have been disappointing and so
have attempts to improve results using a combination
with cytotoxic chemotherapy. The most promising area at
this time is with altered fractionation regimes of radio-
therapy. There is now evidence that human tumours have a
capacity for rapid repopulation during a course of treatment,
suggesting that the overall duration of any course of
radiotherapy should be kept as short as possible (accelerated
radiotherapy). It has further been suggested that the in-
cidence of late radiation damage may be reduced when
treatment is given in a large number of small fractions
(hyperfractionated radiotherapy). A scheme of continuous
uninterrupted hyperfractionated, accelerated radiotherapy
(CHART) used at Mount Vernon is giving promising results
with 15 of 36 (41%) of patients going into 'complete
radiological regression' a figure which can be compared with
9 of 62 (15%) in a previous series. Of the patients who were
assessable at one year 18 of 26 (70%) remain alive. Such
observations give promise for a real advance in the care of
patients with bronchial carcinoma.
Chemotherapy for non-small cell lung cancer (NSCLC)
N. Thatcher
Department ofMedical Oncology, Christie Hospital and Holt
Radium Institute, Manchester, M20 9BX, UK.
Firm evidence to support patient benefit resulting from
chemotherapy for NSCLC until recently was lacking. During
the 1970s there was a tendency to combine single agents with
low activity in the hope of obtaining a higher response rate
and increased survival. These older drug combinations, e.g.
the BACON regimen gave an initial response rate of 43%
which fell in subsequent studies to 21%. The median survival
was 4 months and there was also considerable toxicity. Our
use of cyclophosphamide at doses up to 3.5 gm2 (alone or
with prednisolone or C.parvum) and etoposide (300-
900mgm-2) as bolus or 24h infusions failed to improve the
response rate above 20%. In the 1980s interest in chemo-
therapy for NSCLC increased following the work of Gralla
and his colleagues. The combination of cis-platin and vin-
desine gave response rates of 43% and a median survival of
22 months in responders. In contrast to the earlier studies
consistent response rates of 30% (22-46%) have been
achieved with cis-platin chemotherapy regimens.
Of the 51 drugs evaluated in 134 phase II studies, only 4
have clear antitumour activity with an objective response
rate of 20% or more. The most active single agents and
mean response rates include ifosfamide (26%), cis-platin
(20%), mitomycin C (20%) and vindesine (17%). The
Manchester group has concentrated on the use of ifosfamide;
when single agent ifosfamide was used as a bolus (5gm-2)
in patients with progressing NSCLC a 29% response rate
was achieved. Moreover, there was an improvement in the
Karnofsky score by two steps or more in a further 31% of
patients. A second study using the two alkylating agents
cyclophosphamide (2.5 gm-2) as an infusion over 3 h with
ifosfamide 3.5gm-2, given at the mid-point of the infusion
with appropriate mesna, produced a response rate of 38%
and a 7% complete response rate. Again the patients'
Karnofsky score improved: 23% of patients before chemo-
therapy had a score >70 which improved to 59% after
treatment. The median survival, however, in these two
studies of patients with progressing NSCLC was 5 months.
These and other studies have indicated that ifosfamide can
be given by bolus or short infusions rather than the conven-
tional 24h or 5 day in-patient regimens. Ifosfamide and
mesna are stable for over 7 days and can also be considered
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Recently combinations of ifosfamide, mitomycin and C
and cis-platin in good performance status, NSCLC patients
have given response rates of -50% or more (Cullen p. 893,
Giron - pers' comm., 1987). The use of high dose quad-
ruple chemotherapy with the addition of mustine to the
above three agents with ABMR has also resulted in response
rates of 40% or more with 15% complete response in
patients with progressing NSCLC.
The optimal chemotherapy for NSCLC has not yet been
determined and strict protocol management is mandatory.
As response rate and survival are correlated in many studies
with initial performance status, this and other patient charac-
teristics must be fully described. Symptomatic benefit of
treatment for NSCLC should now also be reported together
with the more usual response, toxicity and survival data.
MRC lung cancer working party multi-centre studies in small
cell lung cancer
D.J. Girling
MRC Cardiothoracic Epidemiology Unit, Brompton Hospital,
London, SW3 6HP, UK(on behalfofthe Working Party).
In the early 1970s small-cell lung cancer was known to be
sensitive to radiotherapy and to combinations of chemo-
therapeutic agents, but the best ways of using these mod-
alities had yet to be determined. Between March 1975 and
April 1977, 253 patients with small-cell cancer of limited
extent were allocated at random to treatment with either
thoracic radiotherapy alone consisting of 30Gy in 15 frac-
tions over 3 weeks or the same radiotherapy followed by 10
alternating 3-drug and 2-drug courses at 3-week intervals of
cyclophosphamide 500mgm 2 and methotrexate 50mgm 2
on each occasion and CCNU 50mgm-2 on the first and
alternate courses thereafter. Survival was significantly pro-
longed in the series which received chemotherapy (P<0.01,
long-rank test), the median survival being 43 weeks com-
pared with 25 weeks in the series which received radio-
therapy alone. However, disease-free 3-year survival was
poor in both series.
In the above study, chemotherapy had not been started
until 3 weeks after completion of the radiotherapy and it was
thought that this delay may have been partly responsible for
the small proportion of 3-year survivors, small-cell cancer
being known to metastasise early. The next study was
therefore undertaken to examine whether, in patients with
limited disease, treatment with radiotherapy followed by
chemotherapy (using the same regimens as above) could be
improved by giving two courses of chemotherapy before the
radiotherapy. Between April 1977 and January 1981, 190
patients were allocated at random to either radiotherapy
followed by 10 courses of chemotherapy, or 2 courses of
chemotherapy followed by radiotherapy followed by 8
courses of chemotherapy. There was no statistically signifi-
cant difference in survival during 3 years, and the survival
rates at 3 years were again very low. Although there was
evidence that the appearance of metastases was slightly
delayed in the series which received 2 courses of chemo-
therapy before radiotherapy, this difference had disappeared
by 12 months.
Because of the potential toxicity of chemotherapy, in the
next study it was decided to investigate different durations of
chemotherapy. Between June 1981 and February 1985, 542
patients with either limited or extensive small-cell lung
cancer were all prescribed 6 courses of chemotherapy on 3
consecutive days at 3-week intervals comprising etoposide
120mgm-2, cyclophosphamide 1 gm 2, methotrexate
35mgm-2 and vincristine 1.3 mgm-2 (max. 2.0mg) on day
1, and etoposide alone on days 2 and 3, patients with limited
disease receiving, in addition, thoracic radiotherapy 40 Gy in
15 fractions over 3 weeks between the second and third
course. Patients in partial or complete response at the time
of the 5th course were then allocated at random either to no
further chemotherapy after the 6th course or to 6 more
courses. There was no satistically significant difference in
survival during 3 years, and so in the current study (the fifth
small-cell study), we are investigating the possibility of
reducing the duration of chemotherapy even further. Three
regimens are being studied, (1) 6 courses or (2) 3 courses of
etoposide, cyclophosphamide, methotrexate and vincristine,
and (3) 6 courses of a new regimen of etoposide and
ifosfamide 5gm-2. At the current rate of accrual, we expect
a planned intake of 400 patients to be completed in about
July 1988. An important feature of these last 2 trials is
studying the quality of life of the patients, including the use
of a daily diary card completed by the patients themselves.
The Working Party is also cooperating with the European
Organisation for Research and Treatment of Cancer
(EORTC) in a randomised trial of surgery followed by 5
courses of chemotherapy on 3 consecutive days at 3-week
intervals comprising etoposide 100mgm-2, doxorubicin
45mgm 2 and cyclophosphamide 1 gm-2 on day 1, and
etoposide alone on days 2 and 3, compared with surgery
alone in the treatment of carefully staged Stage 1 disease,
viz. TiNo, TIN1 or T2NO disease.
Finally, the Working Party is conducting two trials in
non-small-cell lung cancer: one comparing two regimens of
palliative radiotherapy in the treatment of patients with
inoperable disease, and the other investigating the role of
postoperative radiotherapy.
Clinical trials in small cell lung cancer (SCLC)
R. Souhami
University College and Middlesex School ofMedicine,
University Street, London, WCIE 6AU, UK.
Combination chemotherapy has improved median survival in
SCLC, but the proportion of patients surviving 5 years is
less than 2%. Both short-term and long-term prognosis
depend on the extent of disease at presentation. This is
usually defined by imaging techniques (bone and liver scans)
but prognosis can be as accurately assessed by simple clinical
and biochemical criteria. Imaging techniques are of special
value if thoracic radiation is planned as part of treatment. In
patients with metastatic disease at presentation (70% of
cases) less than 1% will be alive at 2 years. In this group
intensification of chemotherapy increases response rate but
does not improve survival. Several regimens have been
evaluated in which the aim has been to simplify chemo-
therapy and to minimise the period spent in hospital, but
there have been few studies in which these regimens have
been compared with combination chemotherapy so the effect
on survival is not known. Quality of life assessments are also
lacking and more studies are necessary to know which
category of patients are best treated in this way.
In limited stage disease combination chemotherapy pro-
duces regression of tumour in up to 90% of patients. This is
associated with good palliation of the symptoms from the
tumour. At 2 years approximately 10% of patients are alive
in unselected series. Intensification of induction chemo-
therapy is associated with a somewhat higher response rate
but, as yet, no convincing improvement in survival. Shorter
and more intensive combinations are being evaluated. There
is some evidence that cyclical alternating chemotherapy has
some advantage over the same regimen continued over
several cycles.
The role of thoracic radiation continues to be evaluated.
Controlled trials have used a variety of dose schedules and
the timing of radiation in relation to chemotherapy has also
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survival advantage with combined treatment, but others have
not. Local recurrence is delayed or prevented by radio-
therapy in many of these studies, even when survival is not
altered. The emphasis must therefore be on improvement of
chemotherapy before the impact of local treatment will be
significant. For similar reasons the effect of 'debulking'
surgery on survival is likely to be small. To date the
favourable results of uncontrolled trials of surgery are likely
to be attributable to case selection.
Role of radiotherapy in small-cell lung cancer
A. Gregor
Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
About 75% of all limited disease patients achieving complete
remission with chemotherapy will relapse within the first 2
years and the overwhelming majority will do so in the area
of bulk primary disease. If local radiotherapy reduces this
relapse rate then improvements in disease-free and overall
survival could be expected. Several randomised studies com-
paring chemotherapy and irradiation to chemotherapy alone
have failed to show convincing evidence of better survival,
although combined modality therapy significantly reduced
local recurrence at a cost of increased toxicity. There was
little or no effect on median survival but in the majority of
studies long-term survival was higher in the combined mod-
ality arm (Dombernowsky et al., In 2nd World Conf. Lung
Cancer, Excerpta Medica, p 149, 1980; Souhami et al., Br
Med. J., 288, 1643, 1984; Perez et al., J. Clin. Oncol., 2,
1200, 1984; Fox et al., Int. J. Radiat. Oncol. Biol. Phys., 6,
1083, 1980; Bunn et al., Proc. Amer. Soc. Clin. Oncol., 2,
200, 1983). There are a number of reasons why a reduction
of local relapse from 70 to 30% will not necessarily lead to
survival gain. Firstly reduction of chemotherapy dosage due
to toxicity compromises the effectiveness of systemic treat-
ment and leads to increased distant failures. Secondly, the
dose in most studies was too low for durable control, and
thirdly the scheduling of multi-modality treatment may be
suboptimal.
Sequencing of chemotherapy and irradiation has been
addressed in a number of studies. The NCI reported ex-
tensively on a group of patients treated with CAV chemo-
therapy and irradiation regimens and showed a high
complete remission rate of 77% but also 10 to 30%
fatal toxicity. The best survival (50% 2 year survival for 75
patients) was achieved in a group receiving concomitant
conventionally fractionated radiotherapy. Administration of
concurrent 'up front' radiotherapy is not without problems.
Shrinking field techniques and individualised shielding blocks
are imperative to achieve acceptable toxicity. The CALGB in
a 3 arm randomised study compared concurrent and se-
quential radiotherapy to an arm receiving radiotherapy
alone. Significant advantage in local control and 2 year
survival was shown for the combined modality arms with
sequential scheduling achieving 25% disease-free survival at
2 years as compared to 8% for chemotherapy alone
(P<0.0001). Chemotherapy dose reductions and toxicity
were common in the concurrent treatment arm (Perry et al.,
New Engl. J. Med., 316, 912, 1987). A different approach
intercalating irradiation between courses of chemotherapy
has led to impressive 30% two year disease-free survival in
an uncontrolled group of patients (Arrigade et al., Int. J.
Rad. Oncol. Biol. Phys. 11, 1461, 1985). Reported toxicity is
acceptable with 10-15% of patients having symptomatic
pulmonary fibrosis.
Studies investigating schedule, dose and fractionation to
achieve the best therapeutic gain are necessary, as local
control only begins to play a part when systemic relapse
recedes as a threat. In small cell lung cancer this situation is
still unfortunately remote.
The risk of CNS relapse in small cell lung cancer is a
cumulative 40% at 2 years. Prophylactic cranial irradiation
(PCI) in doses of 30-40Gy to the whole brain will reduce this
to 10%. Increasing numbers of spinal and CSF metastases
in prophylactically treated patients demonstrates the evolving
problem (Komaki et al., Int. J. Clin. Oncol., 6, 515, 1983).
Neural axis irradiation (Byhart et al., Int. J. Clin. Oncol., 8,
509, 1985) has been proposed but its avoidable haemato-
logical toxicity makes its use in combined modality treat-
ments difficult. Concerns about late morbidity in long-term
survivors of small cell lung cancer and lessons learned from
treatment of acute lymphoblastic leukaemia with combined
chemotherapy and CNS irradiation should lead to the design
of safe and effective studies. It is reassuring to know that
most of the small number of long-term survivors in a large
European study have retained their pre-treatment life style
(Osterlind, J. Clin. Oncol., 4, 1044, 1986).
Small cell lung cancer requires an active multi-disciplinary
approach. Whilst present day chemotherapy has reached a
plateau, a number of radiotherapeutic questions can and
need to be answered. Well organised and controlled multi-
centre studies are needed to identify the true role of radi-
ation in this disease.
The role of surgery in the treatment of small cell lung cancer
M.J. Drakeley
Regional Adult Cardiothoracic Unit, Liverpool, U.K.
Attitudes to the role of surgery in the treatment of small cell
lung cancer have changed most dramatically over the last
three decades. There is little doubt that a major influence on
the attitude of clinicians towards the place for surgery in the
treatment of this highly malignant tumour was the publi-
cation in 1966 ofthe Medical Research Council's comparative
trial of treatment with surgery and radiotherapy. Subsequent
follow up data presented in 1969 and 1973 persuaded many
surgeons to stop operating on patients, even though many
had patients surviving 10, 15 or even 20 years after resection.
The quest to find the most effective cytotoxic agent or
combination of chemotherapeutic drugs coincided with the
appearance of the fibreoptic bronchoscope. This enabled
chest physicians to become oncologists - making the diag-
nosis for themselves and determining the patient's treatment,
whether or not he or she was suitable for resection and
without, in many instances, consulting with a surgeon.
The development of diagnostic aids such as ultrasound,
isotopic scanning and computerised tomography has helped
in eliminating the unnecessary exploratory operation.
Mediastinoscopy has contributed to a more accurate pre-
operative staging of the disease and a reduction in the
number of operations performed.
What then are the surgical options available to patients
with small cell carcinoma? They are as follows:
1. Surgical resection only.
2. Surgical resection with pre or post operative radio-
therapy, local or cranial.
3. Surgical resection with pre or post operative chemo-
therapy.
4. A combination of 2 and 3.
5. Surgical resection with immunotherapy.NATIONAL LUNG CANCER CONFERENCE 889
There are few who believe that surgical resection alone is
the treatment of choice, preferring to follow resection with
adjuvant radiotherapy or chemotherapy, in spite of surgical
series producing 5 year survivals of over 30%. A series of 364
resections in Liverpool operated on during a 20 year period
has resulted in 22 patients surviving for more than 15 years
and many of those surviving for more than 5 years dying
from causes unrelated to their primary disease.
The results of combination treatment with pre or post
operative radiotherapy have been disappointing, largely due
to the small number of patients treated.
There is no doubt that small cell lung cancer is highly
responsive to chemotherapeutic agents and as a result, post
operative chemotherapy has found considerable favour and
yet long term results are little better than surgery on its own.
Pre operative chemotherapy, particularly if the regimen takes
several weeks to complete, may result in patients initially
considered suitable for reaction becoming unsuitable, in
spite of the chemotherapy.
Although it is probable that the major advance in the
treatment of small cell lung cancer will be due to the
development of a chemotherapeutic drug or drugs, there still
remains a place for surgery and I feel strongly that patients
should not be denied a potentially curative operation with
experimentation being confined to those who cannot be
helped surgically.
Therapy of small cell lung cancer: New approaches
J. Klastersky
Service de Medecine Interne et Laboratoire d'Investigation,
Clinique H.J. Tagnon, Institut Jules Bordet, Centre des
Tumeurs de l'Universite Libre de Bruxelles, I rue
Heger-Bordet, 1000 Bruxelles, Belgium.
Small cell lung cancer (SCLC) remains a major challenge in
oncology today. Overall, despite the high initial response to
chemotherapy, the cure rate for patients with SCLC remains
distressingly low. The conclusion from the Second Workshop
of the International Association for the Study of Lung
Cancer (IASLC) was that, after a period of rapid progress in
the 1970s, therapeutic results appear to have reached a
plateau over recent years. Nonetheless, numerous reports
continue to appear in the literature each month, making it
difficult for the practising oncologist to retrieve significant
information. It is the purpose of this short review to
concentrate on the major issues which have still attracted
interest during these 2 past years and to analyse critically the
potential values of these contributions.
Unfortunately, there is nothing new in the management of
SCLC today. Chemotherapy, despite the introduction of
etoposide (VP16), carboplatin and ifosfamide, remains
locked into achievements that were available 10 years ago or
even earlier. Maintenance chemotherapy, alternating 'non
cross-resistant' combinations and intensive treatments, with
the presently available drugs, have failed to improve the
prognosis of patients with SCLC. The addition of radio-
therapy to chemotherapy is no advantage either.
Truly limited disease should definitely be treated with
chemotherapy followed by surgery, as the potential for
prolonged survival looks realistic. Therapy of more extensive
disease still remains a challenge; despite the failure of early
and late intensification programmes, more aggressive initial
multi-drug therapy, which has proven effective in non
Hodgkin lymphomas, might be an attractive approach.
Information derived from biologic studies of both the
tumour and the host, as well as the development of new
active cytostatic agents, look to be the most promising
avenues to more effective control of SCLC.
New drugs in the treatment of lung cancer
J.F. Smyth
Department ofClinical Oncology, Western General Hospital,
Edinburgh, EH4 2XU, UK.
There are currently 4 major considerations in new drug
development to improve on the results of existing chemo-
therapy. Firstly, the development of analogues of existing
agents to reduce toxicity. Secondly, the development of
drugs with novel structures, thirdly, unexpected results in
model systems, and fourthly, the interaction of cytotoxic
drugs with biological response modifiers. As regards tumour
models, significant progress has been made to refine the
appropriateness of in vitro human lung cancer cell lines and
the use of human lung cancer xenografts in immune deprived
mice. A large number of cell lines are now available and the
recent development of a European Xenograft Collaboration
under the auspices of the Early Clinical Trials Group of the
EORTC is facilitating the rapid assessment of potential new
drugs in human lung cancer xenografts in nude mice. These
improvements in tumour modelling are much needed for a
review of the recent literature shows that very few new
agents have proved clinically useful when tested in patients.
In small cell carcinoma of the bronchus one of the few trials
demonstrating positive activity has come from Bork et al.,
who report activity for VM-26 in a group of 33 elderly
patients who had not received any prior chemotherapy. An
objective response was achieved in 30 out of 33 patients
(90%) with 10 (30%) achieving complete remission. These
data highlight the importance of testing new agents in
patients who have not received prior chemotherapy for
whom multiple drug resistance and bone marrow toxicity
frequently result in negative assessments. For non small cell
tumours the response rates to all cytotoxic drugs remain low
but there is emerging a clear distinction between adenocarci-
noma and other histological sub-types. Cis-platinum and
vindesine remain the two most active agents with recent
negative phase II studies reported in trials of doxorubicin,
mitozantrone, ACNU, aclaycinamicin and idarubicin. Of
recent agents tested with positive result in xenograft studies
the new nitrosourea TCNU (tauromustine) has shown acti-
vity in adenocarcinoma of the lung with one complete and
six partial remissions out of 49 patients. The previously
reported interaction of cis-platinum with alpha interferon in
squamous cell lung cancer xenografts is now being inves-
tigated in clinical trials. Interferon is known to be inactive in
human lung cancer and the reasons for its potentiation of
cis-platinum in xenograft studies remains unexplained.
Studies to investigate whether this is an effect on the host
immune system, a non-immune host tumour interaction or a
direct effect are the subject of intense investigation. Lung
cancer remains one of the major therapeutic problems in
oncology and there is an obvious need for the development
of therapies with a higher response rate than cytotoxic drugs
have produced in the past. The modification of cytotoxic
drug action by biological response modifiers may assist in
this very difficult therapeutic challenge.890 NATIONAL LUNG CANCER CONFERENCE
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Biology of lung cancer
Neuron-specific enolase, CEA, and acute phase proteins in the
monitoring of small cell lung cancer
E.H. Cooper1, M.F. Muers2, M.D. Peake3, L. J0rgensen4
and H.H. Hansen4
1Unitfor Cancer Research, University ofLeeds, LS2 9NL;
2Killingbeck Hospital, Leeds; 3Pontefract General Infirmary,
Pontefract, UK; and 4Finsen Institute, Copenhagen, Denmark.
The patterns of evolution of serum levels of NSE, CEA and
acute phase proteins have been studied in 80 patients with
small cell lung cancer from presentation until death.
NSE appears to be the most sensitive indicator of recur-
rence, rising or elevated in 90% of the patients. The changes
in CEA can reflect the evolution of the disease, but only
- 45% ofpatients' tumours produce a raised CEA. These two
markers can show divergent results after starting treatment,
suggesting the rapid destruction of the NSE-producing cells
by chemotherapy. The acute phase reaction varies consider-
ably and integrates the effects of stimuli from the local
interaction of the tumour and host tissues as well as
coincidental infection.
Sublines of a human bronchial carcinoma line with differing
properties
M.R. Daniel, C. Walker & D. Pumford
Clatterbridge Cancer Research Trust, J.K. Douglas Cancer
Research Laboratories, Clatterbridge Hospital, Bebington,
Merseyside, L63 4JY, UK.
A line of epithelial cells (IPT), established in 1982 from a
poorly differentiated bronchial carcinoma and grown from
its 3rd month in vitro in serum-free medium, has been found
to release into the medium one or more constituents, of MW
30-100 KD, which can be shown to be angiogenic (Kumar et
al., Int. J. Cancer, 32, 451, 1983), mitogenic (Walker et al.,
Cell Biol. Int. Rep., 8, 731, 1984) and chemotactic (Daniel et
al., Cell Biol. Int. Rep., 11, 235, 1987) for human umbilical
vein endothelial (HUV) cells. When the line had been in
cultivation for 12 months, a minor component which forms
clearly demarcated islands of small, phase-dense cells was
isolated, and from it were grown 2 subpopulations, lPTV2/7
and IPTV2/10. In stationary culture in serum-free DMEM
without supplementation, the three lines grow both in sus-
pension and attached to plastic; all possess the surface
component that binds anti-epithelial surface antibody. The
subpopulations grow more slowly than the IPT cells and,
unlike these, show some morphological organization, form-
ing rods and rings of mutually adherent cells in which
desmosomes are demonstrable at the intercellular junctions.
Continued cell division gives rise to 3-dimensional structures
which, unlike the aggregates formed in suspension by IPT
cells, cannot be disrupted mechanically without cellular
damage. All three lines are angiogenic on the chorioallantoic
membrane of the fowl egg, but whereas IPT cells spread
from the site of explanation, 1PTV2 cells remain as a
localised mass. A comparison is being made of the results of
the subcutaneous implantation into MFI-nu/nu mice of cells
from the three lines.
Epidermal growth factor receptor (EGF-R) and cellular DNA
content in non small cell lung cancer, clinical and biological
signiricance
H. Dazzil, P.S. Hasleton2, T. Roberts2 & N. Thatcher'
Department of'Pulmonary Oncology and 2Pathology,
Wythenshawe Hospital, Manchester, UK.
Epidermal growth factor (EGF) is a small protein that
stimulates cell proliferation and/or cellular differentiation in
a wide range of cell types. To respond to EGF, the cell must
express a receptor, the epidermal growth factor receptor
(EGF-R). EGF-R with the exception of the circulating cells
of the haematopoietic system is ubiquitous in man. Over-
expression of EGF-R has been reported in epidermal car-
cinoma and in various primary brain tumours. In breast
cancer a correlation between poor prognosis and high
expression of EGF-R was found, and less differentiated
melanomata in cell lineages with epitheloid morphology
are positive for EGF-R, whereas the more differentiated
dendritic types are not.
The expression of EGF-R in non small cell lung cancer as
detected by immunohistochemistry on paraffin embedded
sections has in a retrospective study been compared with
aneuploidy, proliferation index, histological type, tumour
differentiation and survival.
Differentiated squamous cell carcinoma and adenocarci-
noma express EGF-R in over 80%, the less differentiated
types express it only in 55%.
Initial data show that tumours with high proliferation
index express less EGF-R on the cell surface. The expression
of EGF-R may be ofprognostic value.
Malignant pleural mesothelioma; analysis of cellular DNA
content and expression of epidermal growth factor receptor
(EGF-R)
H. Dazzil, P.S. Hasleton2 & N. Thatcher1
'Department ofPulmonary Oncology and 2Pathology,
Wythenshawe Hospital, Manchester, UK.
Mesothelioma can be divided into solitary (localised) or
diffuse, benign or malignant types. Malignant mesothelioma
form a variety of histologic patterns with the majority
having an epithelial or mixed epithelial/mesenchymal con-
figuration. The pure mesenchymal form is the least common.
In a retrospective study we analysed ploidy and prolifer-
ation index by flow cytometry in 180 samples of 84 patients
(post mortem and biopsy specimens). In addition in the 35
patients where biopsies were available, the expression of
EGF-R, detected by a monoclonal antibody (F4-Ab) in
paraffin embedded sections, was examined.
The initial data show that in the epithelial type <50%
EGF-R were detected and in the mesenchymal type only
25%. The poorly differentiated tumours express more
EGF-R than the better differentiated ones. The mesenchymal
subgroup shows more frequent aneuploidy (in 87.5%) than
the epithelial one (53.3%), and in the mixed cell aneuploidy
was detected in 71.4% The clinical relationship of the above
features are to be analysed.
Combination therapy with interferon and cytotoxic drugs in
human lung cancer: Xenograft and clinical studies
R.J. Fergusson, L.E. Anderson, & J.F. Smyth
Imperial Cancer Research Fund Medical Oncology Unit,
Western General Hospital, Edinburgh, EH4 2XU, UK.
We have extended our previous report (Cancer Res., 46:NATIONAL LUNG CANCER CONFERENCE 891
4916, 1986) showing that human alpha-2 interferon (IFN)
can enhance the activity of certain cytotoxic agents (cyclo-
phosphamide, ifosfamide and CDDP) in non-small cell lung
cancer to other classes of anti-cancer drugs and other
tumours. Doxorubicin, etoposide, vindesine, two platinum
analogues and a new nitrosourea have been tested in com-
bination with low doses of IFN in a squamous bronchial
carcinoma xenograft. Although this tumour was generally
resistant to most drugs, in all cases increased activity was
seen with the combination compared with the drug given
alone. IFN as a single agent had no effect. No such
interactions were seen in two small cell xenografts with IFN
in combination with four different drugs.
Using information from experiments in the xenograft
model assessing different dosing schedules, we have under-
taken a pilot clinical study of IFN and CDDP in patients
with non-small cell lung cancer. Preliminary results from this
study will be presented.
The value of tumour markers in lung cancer
S.A. Gomm1, B.G. Keevil2 & N.T. Thatcher1
'Department ofChest Medicine, 2Department ofChemical
Pathology, Wythenshawe Hospital, Manchester, M23 9LT,
UK.
The pre-treatment serum levels of neuron specific enolase
(NSE), phosphohexose isomerase (PHI) and circulating
immune complexes (CC) as tumour markers were compared
to measurements of standard haematology and biochemical
indices as an aid to the differentiation of tumour cell type,
disease extent, response to therapy and survival in 76
patients with lung cancer. There were 57 males and 19
females, median age 59 years (range 31 to 78 years), 42
patients had small cell (SCLC) and 31 patients had non-
small cell lung cancer (NSCLC) and 3 were of unknown
histology. We observed elevated (NSE>12.5ngml-1,
PHI>1201Ul-1, CC>55mgl-1) levels in 52.6% of cases
for NSE, 85.5% for PHI and 47.6% for CC. NSE was
significantly elevated in 61% of patients with SCLC com-
pared to 40.6% with NSCLC (P<0.005), but there was no
significant difference between limited and extensive disease
in SCLC. CC levels were significantly raised in NSCLC
(71.8%) compared to 31.7% in SCLC (P<0.05). Serum
albumin levels were decreased significantly (<30gl-1) in
NSCLC, 46.9% compared to 14.6% in SCLC (P<0.005).
Overall pre-treatment values of NSE, PHI and CC were not
related to the clinical response to therapy, however, patients
with an elevated GGT, AP or a low serum albumin were
non- or partial-responders. Non-responders had 7 or more
abnormal haematology and biochemical indices. Median
survival was 10 months for the 76 patients and was not
influenced by the levels ofindividual tumour markers, but was
significantly shortened (7 months to 8 months, P<0.00001)
when more than 4 abnormal indices were present.
Serum C-reactive protein concentrations during chemotherapy
for small cell carcinoma of the lung. A prospective serial study
in 48 patients
C.R.K. Hind1, & E. Lockey2
1Royal Liverpool Hospital, Liverpool, L7 8XP; and 2London
Chest Hospital, London, E2 9JX, UK.
Problems in patients with small cell carcinoma of the lung
(SCCL) include assessment of tumour response to chemo-
therapy and early recognition of recurrence. No single
laboratory abnormality is specific for SCCL, so these assess-
ments are made by radiological techniques which are expensive
and of variable accuracy. Serum C-reactive protein (CRP)
levels rise nonspecifically in response to tissue injury and
retrospective studies have suggested that these levels closely
reflect tumour mass in carcinoma of the breast, colon and
stomach. Serial serum CRP measurements were therefore
performed prospectively in 48 patients undergoing chemo-
therapy for SCCL. No correlation between initial CRP levels
and extent of disease was possible since several patients had
just undergone biopsy procedures or had other conditions,
e.g. infection) which in their own right result in an elevated
CRP level. However, 2-4 weeks after the first chemotherapy
the serum CRP was normal in 26/39 cases (of which 7
relapsed within 3 months) and raised in 13/39 (2 relapsed
within 3 months). CRP sensitivity (proportion with raised
levels) for extrathoracic relapse (liver, bone, brain) was 71%
(10/14), and for intrathoracic relapse 24% (4/17). A raised
CRP level only preceded clinically detectable relapse in 7%
(1/14), though predicted unresponsiveness to relapse chemo-
therapy in all three cases. In conclusion, this study suggests
that serum CRP levels only provide an accurate assessment of
tumour response to relapse chemotherapy and not to initial
treatment.
The detection of occult bone marrow metastases from small
cell lung cancer (SCLC) using immunocytochemistry
P.R. Kelsey
Department ofHaematology, Manchester Royal Infirmary,
Manchester, UK.
The application of immunocytochemistry to routine bone
marrow smears as an aid to the detection of certain types of
metastatic bone marrow involvement has been described
(Fhosh et al., Br. J. Haematol. 61, 21, 1985) and it can be of
particular value in the identification of isolated suspicious
cells. We set out to discover whether the sensitivity of bone
marrow aspirates in the detection of SCLC could be in-
creased by supplementing routine Romanovsky staining with
immunoalkaline phosphatase staining using suitable primary
antibodies. Two monoclonal antibodies were used: IJ13A, an
antibody reactive with antigens expressed on cells of neural
crest origin and LP34, reactive with cytokeratin. Marrow
was aspirated from a single site on the posterior iliac crest
and 6 smears prepared. Two smears were stained with May
Grunewald Giemsa and 2 with each of the monoclonal
antibodies mentioned above using a three stage immuno-
alkaline phosphatase technique. Material from 40 patients
was examined and in 5 there was evidence of obvious bone
marrow involvement on the Romanovsky stained slides. In
all 5 of these cases the tumour cells stained strongly with
UJ13A, but in only 3 were they stained by LP34. In no
case did immunocytochemistry detect occult tumour cells in
those marrows which had appeared morphologically normal.
Whilst the strong positivity in the morphologically obvious
cases attests to the efficacy of the technique, it does not
seem likely that this approach can improve the sensitivity
of routine bone marrow aspiration in the detection of occult
involvement of SCLC.
Immunocytochemical (IC) detection of marrow metastases in
small cell lung cancer (SCLC) with possible clinical
implications
R.C.F. Leonard, F.G. Hay, L.W. Adams, M.A. Cornbleet &
J.F. Smyth
ICRF Medical Oncology Unit, Department ofClinical
Oncology, Western General Hospital, Edinburgh, UK.
In a consecutive series of 27 patients with SCLC we com-892 NATIONAL LUNG CANCER CONFERENCE
pared 3 techniques of detecting tumour cells in marrow:
(1) conventional smear and trephine, (2) haematological
cytospin, and (3) multispot slides after Ficoll Hypaque
separation. Techniques (2) and (3) were based on a panel of
monoclonals against epithelial, neuroendocrine and 'lung
cancer-associated' antigens selected by screening SCLC cell
lines and clinical cancers as well as normal bone marrow. In
18 patients pretreatment, cytospin and smear/trephine were
equivalent, detecting 4/13 cases with otherwise extensive, and
0/5 with otherwise limited SCLC. Multispot examinations
however showed 11/12 extensive and 4/5 limited disease to
have marrow metastases. Serum-free cell culture of marrow
was feasible in 22 cases and all 'multispot positive' cases
grew SCLC-like cells from marrow from 4-36+ weeks. Post-
treatment, 9 patients in clinical CR were reassessed for
chemo-intensification including autologous bone marrow
rescue. 7/9 had marrow involvement by IC of whom 5
subsequently relapsed at metastatic sites 2-6 months later,
regardless of further treatment.
C-reactive protein in bronchial carcinoma
S. Mallya', L. Copeland', R.J. Donnelly2, R. Mallya', &
J.G. Williams'
'Halton General Hospital, Runcorn; and 2Broadgreen
Hospital, Liverpool, UK.
C-reactive protein (CRP) is an acute phase reactant present
in trace amounts in the plasma. Its level rises in disorders
associated with infection, infarction and malignancy. We
wished to determine if its level was a good screening test
for bronchial carcinoma and whether it could discriminate
between localised and metastatic disease. Fifty-three patients
with bronchial carcinoma were studied at initial presentation.
Bony and/or hepatic metastases were detected clinically and
radiologically in 23 of these patients. The control group
comprised 40 patients with benign nodules, effusions or
haemoptysis. C-reactive protein measurements were per-
formed using the EMIT assay (Syva Co.). Median levels
were calculated for each group and inter-group differences
were calculated by Wilcoxon's Rank Sum Test. CRP levels
are not a reliable screening test for bronchial carcinoma as
I1 out of31 patients with localised disease had normal values.
Patients with localised disease had a significantly higher
level than the control group (P<0.01). Patients with hepatic
or bony metastases had a significantly higher level than
those with localised disease (P<0.001). We conclude that
CRP measurements are reliable indicators of hepatic/bony
metastases in bronchial carcinoma but are not useful in
detecting localised lesions.
Characterisation of small-cell lung cancer cell lines established
from both chemosensitive and chemoresistant tumours
R. Milroy, J. Plumb, R. Adamson, S. Banham, & S.B. Kaye
Departments ofMedical Oncology, University ofGlasgow and
Respiratory Medicine and Pathology, Royal Infirmary,
Glasgow, UK.
Small-cell lung cancer is usually chemoresponsive at outset.
However, following complete response to treatment relapse
is a frequent occurrence. Such relapse tumour is often
resistant to further chemotherapy. Comparison of cell lines
derived from pre-treatment and from relapse tumours may
give an insight into the mechanisms of drug resistance. Thus,
we have successfully established 5 small-cell lung cancer
cell lines in vitro from 17 biopsies (1/7 bronchial biopsies
taken via the fibre-optic bronchoscope and 4/10 metastasis).
Three pre-treatment lines were established from: (a) an
endobronchial biopsy from a subsequently chemoresistant
patient (LS106), (b) a metastatic node deposit from a
subsequently chemosensitive patient (LS111) and (c) a cuta-
neous metastasis from an untreated patient (LS11). Two
further cell lines of biopsies obtained from a patient who
relapsed twice following chemotherapy have been established
following passage in athymic nude mice.
These lines grow as floating aggregates of cells in RPM1
1640 culture medium supplemented with FBS (22%)
selenium, insulin and transferrin.
A sub-line of LS112 grows as a monolayer culture in
Waymouths medium containing FBS (10%). The lines have
been characterised by pathological and immunocytochemical
examination. The cells express both dopa decarboxylase and
creatine kinase BB iosoenzyme activities. LS112 monolayer
also expresses creatine kinase MM isoenzyme activity. We
are currently evaluating a suitable chemosensitivity assay for
these cell lines to further investigate the question of drug
resistance.
Problems associated with chemosensitivity measurements of
non-adherent small-cell lung cancer cell lines
J.A. Plumb, R. Milroy & S.B. Kaye
Department ofMedical Oncology, University ofGlasgow,
Glasgow, G12 9LX, UK.
Drug resistance is a major problem encountered in the
treatment of lung cancer. In order to study the mechanisms
of drug resistance we have established a number of small-cell
lung cancer cell lines. These tumours grow mainly as floating
aggregates in vitro, many of which do not disrupt into single
cell suspensions. Thus, conventional chemosensitivity assays
are invalid. Recently, an assay based on the reduction of a
tetrazolium dye (MTT) by live, but not dead cells has been
described. We have characterised and improved this assay to
allow chemosensitivity estimations of both adherent and
non-adherent lung cancer cell lines.
The assay assumes a linear relationship between cell
number and the amount of dye reduced by the cells. We
have shown that this assumption is valid only if the MTT
concentration is varied depending on the cell line used. This
assay can also be used for many non-adherent cell lines.
However, for some early passage small-cell lung cancer cell
lines, the results suggest that drug exposure results only in a
growth delay. Hence, spheroid growth delay measurements
may be of more value for such cell lines.
Assessment of lung cancer; non-small cell.lung
cancer
An evaluation of the palliative role of radiotherapy in
inoperable carcinoma of the bronchus
T.M. Collins, D.V. Ash, H.J. Close & J. Thorogood
Cookridge Hospital, Leeds, UK.
96 patients with inoperable carcinoma of the bronchus were
entered into a prospective study of the effectiveness of
palliative radiotherapy. Major symptoms were well con-
trolled at 3 months (haemoptysis 88%, cough 58%, dys-
pnoea 53%) and 6 months follow up but dysphagia and
extra thoracic systemic symptoms responded poorly. In spite
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ray there was no significant effect on overall performance
status. Some patients felt that the treatment had helped them
even though performance status and symptoms were re-
corded as being worse. Side effects of dysphagia and tired-
ness occurred in 81% of patients but were classed as mild in
40% and 47% respectively and lasted less than 4 weeks in
86%.
There was no correlation between radiotherapy dose or
radiological response and symptom control. The median
survival of the group as a whole was 38 weeks. 14% of
patients were dead within 3 months and were unlikely to
have benefitted from therapy. Better identification of this
group may spare them unnecessary treatment.
Carcinoma of bronchus 1976-1983: A report of the Thoracic
Group of the Yorkshire Regional Cancer Organisation
C.K. Connolly', W.G. Jones2, J. Thorogood3 & C. Head
'Friarage Hospital, Northallerton, North Yorkshire;
2University Department ofRadiotherapy; and 3YRCO,
Cookridge Hospital, Leeds, UK.
20,155 cases of bronchial cancer with survival data were
registered in Yorkshire between 1976 and 1983. During this
period there was a progressive rise in mean age (65.9 to 68.2
years) and in the rate of histological confirmation (45.4 to
58.4%). The annual number of confirmed oat cell cancers
rose from 209 (8.9%) to 308 (12.3%) and squamous case
from 484 (20.5%) to 712 (28.4%). There was a doubling of
histological confirmation of oat cell cancer in patients over
60 and of squamous cancers in patients over 70. Radical
operations increased from 174 (7.4%) to 241 (9.6%). The
number given chemotherapy without histological diagnosis
fell from 98 (7.6%) to 32 (3.1%). No improvement in
survival was seen for squamous carcinoma or in those
treated with radical surgery or radiotherapy. Short term
prognosis was improved in oat cell patients under 60 years
given chemotherapy (P=0.0002). For all bronchial cancers,
2-year survival rose from 6.8% to 9.5% with significant
improvement in subjects over 70 (P=0.0123). As little thera-
peutic advance was made, improved survival, especially in
patients over 70 is more likely to be due to increased
diagnostic activity and patient selection.
Mitomycin, ifosfamide and cis-platin in non-small cell lung
cancer
M.H. Cullen, A.D. Chetiyawardana, R. Joshil & C.M.
Woodroffe
Queen Elizabeth Hospital, Birmingham and 'Manor Hospital,
Walsall, UK.
Mitomycin, ifosfamide and cis-platin are three of the most
active single agents in the chemotherapy of non-small cell
lung cancer. We have combined them in a 24h schedule
(MIC) for a phase 2 study in patients with inoperable non-
small cell lung cancer. The regime consists of: mitomycin
6mgm-2 i.v. bolus, ifosfamide 3gm-2 i.v. infusion over 3h
and cis-platin 50mgm-2 i.v. infusion over 1 h. Mesna is
given with the ifosfamide infusion at a dose of 1 gm-2 and a
further 500mgm-2 bolus is given 3 h later followed by a 6h
infusion (500mgm-2). The anti-emetic regime consists of
lorazepam 2mgm-2 dexamethasone 8mgm-2 and meto-
clopramide 1 mgkg- i.v. 30min prior to chemotherapy,
metoclopramide 9mgkg-1 over 24h and further doses of
dexamethasone 4mgm-2 i.v. 4 hourly.
Forty ambulatory (WHO performance status 0,1 or 2)
patients with inoperable limited (LD) or extensive stage (ED)
disease have entered this study, and 35 are evaluable for
response. Fifteen patients have achieved partial remission
(43%) and 5 have achieved complete remission (14%) as
assessed radiologically. The overall response rate is thus
57%. There have been 14/20 responses in LD (70%) and
6/15 in ED (40%). Thirteen patients have experienced an
improvement in WHO performance status rating. Although
well tolerated in the majority of patients, the principal
toxicity has been vomiting which was severe (WHO 3/4) in
6 patients.
MIC is clearly among the most active combinations in
non-small cell lung cancer and will now be tested in a
randomized trial against no chemotherapy.
Antibody guided targetting of breast cancer and non-small cell
lung cancer using indium-ill labelled HMFGl-F(ab')2
fragments
H. Kalofonos, J. Taylor-Papadimitriou, J.P. Lavender &
A.A. Epenetos.
ICRF Oncology Group, Royal Postgraduate Medical School,
Hammersmith Hospital, Du Cane Road, London, W12 OHS
and Imperial Cancer Research Fund, Lincolns Inn Fields,
London, WC2A 3PX, UK.
F(ab')2 fragments of tumour associated monoclonal antibody
HMFG1 were used for radioimmunolocalisation of primary
and metastatic breast and non-small cell lung cancer.
The antibody was conjugated with DTPA and labelled
with Indium-ill. Radio-labelled antibody was shown to be
stable in vitro and in vivo and there was no significant loss of
immunoreactivity.
10 patients with breast and 11 with lung cancer were
studied by radioimmunoscintigraphy after i.v. administration
of indium-I 11 In-labelled HMFG1 F(ab')2.
Successful localisation was observed in all primary and in
the majority of metastatic lesions. No significant uptake was
observed in normal organs except for liver which accumu-
lated -20% of the injected amount. No toxicity was en-
countered and no human anti-mouse response was detected
in any of the patients even after repeated administration.
Clinical results of pulmonary resections in carcinoma of the
bronchus
D. Kaplan, D. Muehrcke, & R.J. Donnelly
Regional Cardio Thoracic Unit, Broadgreen Hospital,
Liverpool, UK.
Between January 1980 and December 1986, 564 patients
underwent pulmonary resection for malignant disease.
Automatic stapling devices were used to close the bronchus
in all patients. The operative mortality was 4.9% (3.2% in
patients undergoing lobectomy and 8.3% in those under-
going pneumonectomy). The complication rate was 17.3%.
The post-pneumonectomy incidence offistula was 2.8% within
three months of surgery and 4.6% overall. Stapled closure of
one or more hilar vessels was employed in 153 patients.
Pulmonary resection can be performed with acceptably low
morbidity and mortality.
Survival after radiotherapy for lung cancer
L.M. Matheson, S. Capewell, M.F. Sudlow & G.A.
Newaishy
on behalfofthe Edinburgh Lung Cancer Group
Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
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registered 2586 new cases of lung cancer during 1981-84.
Initial treatment options included thoracic irradiation (31%),
surgery (19%) and chemotherapy (12%); 38% received
symptomatic therapy only.
In 1981, 233 patients with non-small cell lung cancer
(NSCLC) were treated with primary thoracic irradiation.
Radical radiotherapy (radical RT, central dose 45-57 Gy)
was given to 41 (17%) patients of whom 32 had positive
histology; 192 received palliative irradiation (palliative RT:
18-30 Gy). Compared with the palliative group, the radically
treated patients were younger (76% vs. 57%<70 years;
P<0.02), fitter (Karnofsky index <80 in 79% vs. 49%;
P<0.001) and had less extensive disease.
After radical RT for histologically proven NSCLC, local
control (radiological CR+PR) was achieved in 25/32 (78%)
and was a prognostic factor for survival; 4 year survival was
12.5% (4/32). After palliative RT, 7/192 survived 4 years.
These data suggest that radical thoracic, irradiation
achieves good local control of disease and may confer a
survival benefit in selected patients with inoperable NSCLC.
Central nervous system (CNS) surveillance with computerised
tomography (CT) and magnetic resonance (MR) imaging in
small cell lung cancer (SCLC): A comparison of imaging
modalities.
T.J. Perren, I.E. Smith, G. Cherryman, J. Husband,
M. Williams & C. Heron
High dose rate intracavitary radiation in the treatment of
carcinoma of the lung
C.G. Rowland & K.M. Pagliero
Departments ofRadiation/Oncology and Thoracic Surgery,
Royal Devon and Exeter Hospital (Wonford), Exeter, Devon,
EX2 5DW, UK.
Endobronchial brachytherapy has been performed up to 30
years in a limited number of centres; mainly on an anecdotal
basis. Unfortunately, due to the limitations and size of
equipment available only a limited number of tracheal and
main bronchial tumours have been accessible by these tech-
niques. Successful treatment of more peripheral tumours
with more sophisticated, safe after loading equipment has
recently been reported from North America. Patients treated
include those who have not only primary tumours but also
recurrences following previous surgery, radiation and chemo-
therapy. In conjunction with the Dutch firm, Nucletron, a
high dose rate micro-selectron has been developed to allow
the passage of a small, intense iridium source of up to
1Ocuries activity. The treatment catheter which is 2mm in
diameter can either be wire guided or directly placed through
the side channel of the more modern bronchoscopes. It can
also be placed transcutaneously, and depending upon the
source activity the treatment time can be as short as 10-
15min.
It is important that the effect of intracavitary radiation
alone in the treatment of lung cancer should be documented
as most other studies have involved multi-modality treat-
ment. A clinical trial supported by the South Western
Regional Health Authority has been set up.
Lung Unit and Department ofRadiology, Royal Marsden
Hospital, Sutton, Surrey, UK.
49 patients with SCLC entering a 3 monthly CT scan
surveillance study designed to detect CNS metastases whilst
asymptomatic, also had MR within 1 week of each CT scan
as part of a second study to compare the 2 imaging
modalities. 2 additional patients with known CNS metastases
were also scanned; 1 at the time of recurrence and the other
3 months after cranial radiotherapy. A Siemens Magnetom 2
tesla (T) unit operating at 1.5T was used. 7mm axial
sections were obtained at 3.5mm gaps using a T2-weighted
sequence with TR 2.7sec and TE of 30+90msec. Abnormal
scans were repeated using T1-weighted sequences. 16 patients
also received 0.4mgkg-1 of gadolinium DTPA IV contrast
medium (Schering UK), post contrast scans were obtained
using T1-weighted sequences.
8 patients developed CNS metastases and 1 had recurrent
metastatic disease; in 8 of these 9 patients lesions were
identified with both CT and MR, and in the 9th pt only on
MR. Of the 8 patients with positive CT and MR, MR was
considered superior to CT in 2 and equivalent to CT in 3.
The remaining 3 patients had multiple lesions, some better
seen with MR and some better seen with CT. 3 patients with
metastases were rescanned after the injection of gadolinium
DTPA and in all instances metastases enhanced strongly
with contrast allowing lesions to be seen with greater clarity
and confidence. Additional lesions were also seen on post
contrast studies. 1 patient scanned 3 months after radio-
therapy to a CNS metastasis showed strong gadolinium
enhancement of the residual lesion, although the CT had
returned to normal; and in another patient, rescanned 2
months after cranial radiotherapy, the residual lesion was
better seen on gadolinium MR than on CT.
These preliminary results suggest MR may be useful in
CNS surveillance ofpatients with SCLC.
A numerical discriminant applied to prediction of survival in
inoperable carcinoma of the bronchus
J. Thorogood, T.M. Collins, D.V. Ash & H.J. Close
Cookridge Hospital, Leeds, UK.
An evaluation of the palliative role of radiotherapy in
inoperable lung cancer revealed that 16 out of 96 patients
studied (17%) were dead within 3 months of treatment and
were unlikely to have benefited from therapy. A statistical
discriminant approach was used to identify a suitable index
to predict survival to 3 months. This index comprised weight
loss in the previous 6 months, performance status, extent of
disease and blood lymphocyte count.
A simple tree diagram was developed for clinicians to
follow through for a given patient, to arrive at one of 16
discrete probabilities of that patient being alive 3 months
later. No calculations are required for its use and it is based
on the index, using four factors only. The survival prob-
abilities ranged from over 0.95 for 3 or 4 factors in the good
prognosis category, to less than 0.20 with 3 or 4 factors in
the poor category.
When applied to a prospectively collected set of 80
patients, the index achieved an accuracy of 97% in predict-
ing those who would survive for longer than 3 months. It
achieved a low accuracy of 26% in those dying before 3
months because these cases presented with 2 good factors
and 2 poor.NATIONAL LUNG CANCER CONFERENCE 895
Sequential combination chemotherapy and radiotherapy in
locally advanced non small cell carcinoma of the bronchus
S.W. Watkin, R.D. Errington, J.A. Green & H.M. Warenius
CRC Department ofRadiation Oncology, Clatterbridge
Hospital, Bebington, Wirral, Merseyside, UK.
The feasibility, effectiveness and toxicity of a new 4 drug
intensive combination chemotherapy regime has been assessed.
Sequential radical radiotherapy was given to all patients
after completion of chemotherapy. Response, local control
and survival following this strategy have been evaluated in a
group of patients with inoperable non-small cell lung cancer.
35 patients, 24 male, 11 female, aged 35-71 years, mean 56.2
years have been entered into the study. ECOG performance
status was 0/1 in 25, 2/3 in 8 and 4 in 2. Histology was
squamous carcinoma 21, adenocarcinoma 6, large cell 2,
undifferentiated in 5 and there was 1 alveolar cell carcinoma.
15 patients were stage III MO and 19 were stage III Ml in
whom 8 had neck nodes as the only site of metastasis.
Patients were given adriamycin 40 mgm 2, vindesine
3 mgm-2, ifosfamide 5 gm-2 with mesna rescue, and cis-
platin 60mgm-2. Four weeks after the last cycle of chemo-
therapy, radiotherapy to a total dose of 4800cGy in 16
fractions was given to the primary tumour. 22 (63%)
patients have received 3 or more courses of chemotherapy
and 25 (71%) have received radiotherapy of whom 14
received wide field radiotherapy and bulk boost to the
planned dose. Response to AVIP chemotherapy was CR 3
(9%), PR 9 (26%), SD 13 (37%), PD 4 (11%). There have
been 2 early deaths (PD in 1, toxicity in 1) and 4 have not
completed chemotherapy. Nadir blood counts in 94 cycles
showed WBC<2.5 x 109 1 1 in 32, Hb< IOg 1 -1 in 18 and
platelets <100 x 109 1 -1 in 13. There were 3 neutropenic
fevers. Median survival is 10 m and 12 m survival was
40%. Local relapse has occurred in 12 patients, 4 of whom
had received DXT 48 Gy, and brain metastases occurred in 6.
A further 6 patients have not relapsed. This strategy produces
favourable response rates with acceptable toxicity.
Small cell lung cancer; new drugs in lung
cancer
Pretreatment prognostic factors in 407 patients with small cell
lung cancer and 134 patients with non small cell lung cancer
H. Anderson1, T. Cerney1, R. Swindell2 & N. Thatchert
1CRC Department ofMedical Oncology; and 2Department of
Medical Statistics, Christie Hospital, Manchester, UK.
In 407 patients with small cell lung cancer (SCLC), 61
pretreatment variables were evaluated by Cox Multiple re-
gression analysis to look at prognostic factors. All patients
received 18 weeks of intensive chemotherapy and thoracic
radiotherapy. 6 variables were found to be the most import-
ant and other factors added no additional prognostic
information.
The prognostic factors were LDH (P=0.0001), stage
(P=0.001), serum sodium (P=0.0009), Karnofsky perfor-
mance (P=0.0121), alkaline phosphatase (P=0.0186), serum
bicarbonate (P=0.0321). A simple scoring system was es-
tablished and analysis distinguished 3 prognostic groups, the
best group containing all the 2+ year survivors and 19% of
these had extensive stage disease.
In 134 patients with non small cell lung cancer (NSCLC),
43 pretreatment variables were evaluated by Cox multiple
regression analysis to assess the effect on prognosis. All the
patients had received ifosfamide chemotherapy for 12-18
weeks and some had also received some cyclophosphamide.
Karnofsky performance was the variable with the most
prognostic importance (P=0.0001). The serum chloride was
of border significance (P=0.04). A scoring system using
Karnofsky performance and chloride divided patients into
prognostic groups and the best group also contained patients
with extensive stage disease.
Patient selection for chemotherapy regimens based on
stage alone may not be adequate.
Small cell lung cancer - therapy with i.v. bolus ifosfamide and
8 day oral VP16
H. Anderson', M.J. Lind', K. Carroll2 & N. Thatcher1
1CRC Department ofMedical Oncology, Christie Hospital,
Manchester; and 2Department ofChest Medicine,
Wythenshawe Hospital, Manchester, UK.
From May 1986, 46 patients with small cell lung cancer have
received therapy with ifosfamide 1.5gmm 2 mixed with
mesna 1.5gmm-2 as a short i.v. infusion in 500ml normal
saline over 30min. Patients received 200mg oral mesna at 4
and 8h after therapy and oral VP16 100mg daily for 8 days.
Patients stayed in hospital overnight the day of chemo-
therapy. Cycles were repeated at 3 weekly intervals if the
WCC was >3.0 x 1091- and platelets > 100 x I091- 1. The
aim was to give 6 courses of CT and reassess. 27 patients (16
male: 11 female) have now completed therapy. The median
age was 63 (45-73 years) 10 patients had limited stage (LS)
and 17 extensive stage (ES) disease (9 liver, 5 bone, 3 nodal).
The median KP before treatment was 60 (range 40-80) and
MRC respiratory score 3 (range 1-5).
A median of 6 courses has been given (range 2-6) and the
10 LS patients have received thoracic irradiation. Toxicity
was little. The median WHO grade for haematological
toxicity was 1 (range 0-3). Nine patients had no haemato-
logical toxicity. Non-haematological toxicity median WHO
grade was I (range 0-3), and usually was transient nausea.
Blood transfusions were given to 8 (30%) patients and i.v.
antibiotics to 6 (22%).
The median KP post treatment was 70 (range 0-100), and
RS 2 (range 1-5). The overall response rate was 33/27
(48%) with 6 (22%) complete remissions. The median survival
was 6/12 for ES and 7/12 for LS disease. This low dose non
toxic therapy is inferior to our other regimens and has
been discontinued.
Chemotherapy plus adjuvant surgery for local small cell lung
cancer
G.F.A. Benfield1, H.R. Matthews2, D.C.T. Watson2,
F.J. Collins2 & M.H. Cullen'
1 WMCRC Clinical Trials Unit, Queen Elizabeth Medical
Centre, Birmingham, B12 2TH; and 2Department of Thoracic
Surgery, East Birmingham Hospital, Birmingham, B9 5ST,
UK.
Chemotherapy is effective radical treatment for small cell
lung cancer (SCLC), but relapse is usual with up to 85% of
tumours recurring at the primary site. Surgery is an effective
debulking agent, but < 10% of tumours are amenable to
this approach because of the early metastasis of SCLC. An
alternative approach would be to combine these 2 modalities
to derive their respective benefits.
Nine patients with local Stage II (T2NlMO) or III
(TIN2MO) SCLC received combination chemotherapy - 2896 NATIONAL LUNG CANCER CONFERENCE
courses of cyclophosphamide, doxorubicin, etoposide, vin-
cristine and methotrexate - followed by adjuvant surgery, to
assess the effectiveness of such a regimen in improving
operability, preventing local relapse and extending survival.
The regimen was well-tolerated and prevented local relapse.
However, the median time to recurrence of disease was 10
months and the median survival time 12 months, results
which are similar to those achieved with chemotherapy and
radiotherapy. Distant metastases, particularly in the brain,
occurred predictably indicating that successful adjuvant sur-
gery, despite preventing local relapse, does not appear to
afford additional survival benefit.
A randomised trial of short courses of intravenous (i.v.)
chemotherapy versus oral (p.o.) out-patient chemotherapy for
small cell lung cancer (SCLC)
B.J. Cantwell1, A.L. Harris1, J.M. Bozzino1, P. Corris2
& D. Veale2, and the North East of England Lung Cancer
Study Group
University Department ofClinical Oncology, Regional
Radiotherapy Centre, Newcastle General Hospital; and
2Department ofRespiratory Medicine, Freeman Hospital,
Newcastle upon Tyne, UK.
A regional randomised trial compared i.v. chemotherapy
versus oral chemotherapy for histologically or cytologically
proven SCLC. Patients were randomised to receive either
p.o. chemotherapy (chlorambucil 6mgm-2 daily for 10 days,
procarbazine 150mg daily for 10 days, prednisolone 20mg
daily for 10 days and VP16 300mg daily for 3 days only) or
i.v. chemotherapy (adriamycin 40mgm2, vincristine 2mg,
VP16 lOOmgm-2, all i.v. on day 1, with oral VP 300mg on
days 2 and 3 - course 1, and for courses 2, 3 and 4,
adriamycin 30mgm-2, vincristine 2mg, VP16 200mgm-2
i.v., plus ifosfamide 5gm-2 and mesna by 24h i.v. infus;on).
Both p.o. and i.v. cycles were repeated every 21 days to a
total of 4 courses. Patients with good response to chemo-
therapy in either arm were given consolidation mediastinal
and prophylactic cranial radiotherapy. 110 patients received
i.v. and 100 p.o. chemotherapy and both arms were matched
for sex, age and performance status. Response rates were:
p.o. (CR)=22%, i.v. CR=22%, p.o. PR=45%, i.v.
PR =50%, in limited (L) stage disease. In extensive (E) stage
disease i.v. chemotherapy produced a greater PR rate (p.o.
PR=27%, i.v. PR=59%; P<0.01). At a median follow up
of 96 weeks L stage patients had better survival than E stage
patients (P<0.01), log rank test, but there were no dif-
ferences between p.o. vs. i.v. treatments overall or within L
stage disease. Patients with E disease had better survival if
given i.v. chemotherapy (P<0.05). There were 8% toxic
deaths in i.v. and 3% in p.o. patients. Short courses of p.o.
out-patient chemotherapy confer equal survival benefit as the
more expensive i.v. chemotherapy for L stage SCLC but i.v.
treatment is better for E stage disease.
Late intensification with high dose melphalan (HDM) +
autologous bone marrow rescue (ABMR) in small cell lung
cancer (SCLC): An analysis of patterns of failure
M.A. Cornbleet, A. Gregor, R.C.F. Leonard & J.F. Smyth
Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
'Complete' remission (CR) rates of 30-50% are regularly
reported in patients with limited stage (LS) SCLC but long-
term disease control is infrequent. Patients with good
performance status and LS in bronchoscopically confirmed
CR (BCCR) were offered late intensification of therapy
comprising HDM (140mgm-2) and ABMR, followed by
radiotherapy (RT) to the primary site (4500cGy in 20
fractions) and prophylactic cranial irradiation (PCI). 23/71
(32%) achieved BCCR after a 12-week induction regimen
comprising methotrexate, cyclophosphamide, etoposide 3
adriamycin x 4. 11 declined HDM and received the same RT.
HDM+AMBR was well tolerated, being associated with
acute nausea and vomiting, predictable myelosuppression
and neutropenic PUO (4 patients - total febrile days= 13)
with no treatment-related mortality. Median disease-free
(DFS) and overall survivals (OS) were: 10 & 12mo after
HDM and 15 & 17mo without. Actuarial 2-year survival
was 0% and 21% respectively. 16/23 patients have relapsed;
8/11 without HDM, 8/12 with. Initial sites of relapse were:
no HDM chest 5 (1 infield, 4 marginal), cervical nodes 1,
liver 1, brain 1 (prior to PCI); with HDM - chest 4 (all
infield), liver 3, brain 1 (prior to PCI). The 4 patients
relapsing initially in the liver had fulminating courses; none
survived >6 weeks. All 5 non-CNS distant relapses had the
primary site controlled until death. We conclude that: (a) 12
weeks' systemic therapy is insufficient for this good pro-
gnosis subset of patients; (2) local control remains a major
problem; (3) possible occult reinfusion of tumour cells in-
dicates the need for improved methods of detection; (4)
although HDM given as late intensification in this dose and
schedule does not significantly enhance DFS or OS, higher
doses and different schedules are feasible and are currently
under investigation.
Testing new drugs in untreated small cell cancer may prejudice
the efficacy of standard treatment: A phase II study of oral
idarubicin in extensive disease
M.H. Cullen, S.R. Smith, G.F.A. Benfield &
C.M. Woodroffe
Queen Elizabeth Hospital, Birmingham, B15 2TH, UK.
The results of standard chemotherapy treatment in small cell
cancer are poor with virtually no long term survivors.
However a number of chemotherapeutic agents, in com-
bination, can provide effective short term palliation and
extension of survival. Conventionally, new drugs are tested
in patients who have failed on standard treatment and thus,
by definition, have multi-drug resistant tumours. It is quite
possible that potentially valuable agents will not be identified
in this setting. Thus a number of investigators have tested
new drugs in previously untreated cases, reverting to stan-
dard treatment in those who fail to respond. We have
evaluated the orally active anthracycline idarubicin
(40mgm-2 in divided doses over 24h) in 22 patients with
extensive stage small cell lung cancer, and report the results
of subsequent i.v. therapy ('CVE'-cyclophosphamide
1000mgm-2, vincristine 1 mgm-2, etoposide 120 mgm-2
i.v. day 1; etoposide 250mgm2, orally in divided doses on
day 2), as well as those of the phase II study.
Of 22 treated patients 3 (14%) responded with 2 complete
remissions. Patients failing to respond promptly, and relapse
cases were treated with CVE. Seven patients did not receive
CVE for the following reasons: early death 4, early CNS
disease 2, refusal 1. Fifteen cases did receive CVE. Of 13
idarubicin failures 9 progressed on CVE, 3 achieved PR and
1 CR. Two idarubicin responders who had CVE achieved
PR and CR. The median survival (MS) of all 22 patients is
136 days. For those with WHO performance scores of 0 or 1
the MS is 189 days and for the rest it is 80 days. Despite a
strictly applied policy of instituting standard i.v. therapy
promptly in static or progressive disease, these results are
inferior to those seen in our centre with standard treatment
from the start, in extensive small cell cancer, especially in
those with poorer performance status.
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often require a rapid and more guaranteed response to their
first treatment and may not be suitable for experimental
therapy.
Prognostic factors in patients with small cell lung cancer
(SCLC)
H.M. Earl', R.L. Souhamil, C.M. Ash', S.G. Spiro2,
D. Geddes3, P.G. Harper4 & J.S. Tobias'
1Department ofRadiotherapy and Oncology, University
College Hospital, London, WCIE 6AU; 2Brompton Hospital,
London, SW3 6HP; 3London Chest Hospital, E2 9JX; and
4Guy's Hospital, London, SE] 9RT, UK.
Analysis of pretreatment variables in 371 patients with
SCLC treated with identical chemotherapy in the context of
a large prospectively randomised clinical trial, demonstrated
that prognosis was strongly correlated with initial perfor-
mance status, plasma sodium and albumin, and plasma
alkaline phosphatase (Souhami et al., Cancer Res., 45, 2878,
1985). Using these parameters 3 prognostic groups were
defined. These prognostic factors were then analysed in 613
patients with SCLC who were included in a prospectively
randomised trial of chemotherapy duration. The prognostic
factors were confirmed, on this new data set, to be predictive
of survival. Plasma alkaline phosphatase at diagnosis was
predictive for early death, and performance status for both
short and long term survival. Long survivors were predomi-
nantly patients with limited disease in the good prognostic
category, whilst the majority of patients dying within 21 days
were in the poor prognostic category. Analysis of the change
in these parameters in response to treatment showed that
clinical response was associated with improved survival, even
in the bad prognostic category. Analysis of prognostic
factors at diagnosis may not only provide guidelines for
selecting patients suitable for intensive treatment, but also
for identifying patients who are at high risk of early death,
and who require modifications of standard chemotherapy.
Sequential analysis of change in prognostic factors in re-
sponse to treatment allows an assessment of the value of
continued chemotherapy in poor risk groups, and a defi-
nition of the criteria of response using biochemical markers.
Prognostic factors in small cell lung cancer - the Edinburgh
experience
S.G. Allan, J.F. Smyth, M.A. Cornbleet & R.C.F. Leonard
Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
Between 1980 and 1986, 297 small cell patients have been
entered into treatment studies in the Edinburgh Medical
Oncology Unit. 81 patients were treated between 1980 and
1982 with methotrexate, CCNU and cyclophosphamide with
or without maintenance therapy (which itself had no survival
impact). In subsequent trials 100 'good prognosis' patients
were treated with methotrexate, cyclophosphamide and VP-
16, and 116 'poor prognosis' with vindesine and VP-16. The
presenting clinical, radiological and biochemical character-
istics were documented and retrospectively analysed within
each treatment category and then in all treatment categories
combined with the aim of identifying prognostic indices.
Applying Mantel Log Rank statistics on actuarial survival
analysis, we found that the most important individual factors
common to all treatment groups were respectively perfor-
mance status, disease extent, age, white blood count and
bone scan. Low haemoglobin (<12gdl-1) and or low serum
sodium (<135mmoll-1) had minor negative influence on
survival (P=0.08 and P=0.06 respectively) but all other
parameters tested i.e. gender, blood platelets, serum LDH,
alkaline phosphatase and albumin were of minor or no
importance in the treatment groups analysed in isolation or
combined. Multivariate analysis (Cox model) confirmed the
adverse affect on prognosis only of increasing performance
status, increasing white blood count and extensive disease
especially when the latter incorporates both liver and bone
or bone marrow.
Sequential induction chemotherapy with late intensification in
small cell lung cancer
J.A. Green, J. Hardman, R.D. Errington & H.M. Warenius
CRC Radiation Oncology Unit, Clatterbridge Hospital,
Wirral, Merseyside, UK.
Seventy-two patients with small cell lung cancer (48 limited,
24 extensive disease) were entered on a protocol comprising
induction with 4-6 cycles of cyclophosphamide 1 gm-2,
adriamycin 40mgm-2 and vincristine 1.4mgm-2 (CAV)
every 21 days for 4-6 cycles. 33 patients achieving complete
remission received intensification with 2 further cycles of
ifosfamide 5 gm 2, mesna 8gm-2, methotrexate 30mgm-2
and etoposide JOOmgm-2/day for 3 days (IME). 6 of the 13
patients in partial remission following CAV achieved a
further remission on IME (response rate 46%). The overall
median survival was 8 months, and of the 33 patients in
complete remission was 11.5 months, with 3 long term
survivors at over 2 years. Median survival in the limited
disease group was 12 months compared with 5.5 months in
the extensive disease patients. There was no significant
prolongation of survival seen in those patients receiving
prophylactic cranial irradiation (10 patients) mediastinal
irradiation (12), or those who had negative second broncho-
scopy examination. This sequential 6-drug regime produces
acceptable response and survival in small cell lung cancer,
but does not produce a cohort of long term survivors.
Contribution of thoracic irradiation to local control in small
cell lung cancer (SCLC)
A. Gregor",2, S.W. Banham', M.A. Cornbleet2,
A.J. Dorward1 & J.F. Smyth2
' West ofScotland Lung Cancer Group, Glasgow; and
2Department ofClinical Oncology, Western General Hospital,
Edinburgh, UK.
The contribution of improved local control to survival is
difficult to assess in diseases where short survival time is
determined by metastatic spread. In SCLC, a number of
regimens of thoracic irradiation are used, often with conflict-
ing results. In order to assess the contribution of convention-
ally fractionated, moderate dose (40Gy in 3/52-45Gy in
4/52) radiotherapy (RT), given to the presentation volume
after a 12-week course of induction chemotherapy, we have
analysed local control in 55 limited disease (LTD) patients
achieving bronchoscopically confirmed complete remission
(CR). Patients were treated in 2 concurrently running studies
(1982-1984) in Glasgow (GL) and Edinburgh (ED). Prog-
nostic features, staging and assessment of response were
similar in both studies. Induction chemotherapy was previ-
ously described. No maintenance chemotherapy or late dose
intensification was given. 44/95 (46%) of LTD patients in
GL achieved CR, 23 were irradiated; 21 control patients
from one participating centre did not receive RT due to
physician's preference. 23/71 (32%) LTD patients in ED
achieved CR, 12 subsequently received melphalan
140mgm2 and are excluded from this study. The remaining
11 patients were irradiated. Local relapse occurred in 11/34
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(32%) of irradiated patients and 15/21 (71%) controls
(P<0.005). It was the sole site of failure in 6 (18%) patients
receiving RT and 8 (38%) controls. Detailed analysis of
primary site relapses is in progress. No significant survival
difference was found between the irradiated and control
group, with median survivals 14 & 12 months respectively.
Conventional RT significantly reduces local recurrence rate
but its impact on survival even in the best prognostic group
of patients is minimal.
Chemotherapy for the elderly with small cell lung cancer
A.M. Hendrick' 3, M.J. Connolly' 2, D.J. Hendrick',
B.M.J. Cantwell3 & A.L. Harris3
Departments of 'Chest Medicine; 2Geriatrics; and 3Clinical
Oncology, Newcastle General Hospital, Newcastle upon Tyne,
NE4 6BE, UK.
Local figures suggest that one third of patients presenting
with small cell lung cancer are over 70 years of age. As
adverse effects from combination chemotherapy at this age
may be increased, we have evaluated the risks against benefit
in 32 such patients receiving short courses of one of two
chemotherapy combinations. Seventeen patients were treated
with a conventional i.v. regimen of adriamycin 40 mgm-2,
vincristine 2 mg and VP 16213 100mgm-2 followed by VP
16213 300mg orally on days 2 and 3. Six patients also
received ifosfamide. The other 15 received oral therapy with
VP 16213 300mg for 3 days and chlorambucil 100mg +
procarbazine 150 mg + prednisolone 20 mg daily for 10
days. Compliance with this treatment was excellent despite
the 99 tablets per course. Treatment groups did not differ in
respect to clinical parameters and response rates (complete
and partial), being 71% for the i.v. and 86% for the oral
therapy. In the i.v. group there were four sudden (presumed
toxic) deaths within the period of the first two courses of
therapy, and a fifth death due to recognised cardiotoxicity.
In addition, non-fatal neutropenic fever occurred in five
subjects and cardiotoxicity in one. By contrast, the only
serious complication in the oral group was a case of non-
fatal neutropenic fever. (P <0.01) Median survival was
6.5m for both treatment groups with only two patients in
each treatment group alive at one year. Thus survival is
inferior to that achieved with younger patients. It appears
that this i.v. regimen is unduly toxic in the elderly but that a
similar and worthwhile survival benefit can be achieved with
oral therapy with minimal toxicity.
Ifosfamide, etoposide and adriamycin in the treatment of small
cell lung cancer
M.J. Lind', H. Anderson', M. Bronchud', N. Thatcher'
& R. Stout2
'CRC Department ofMedical Oncology, Christie Hospital;
and 2Department ofRadiotherapy, Christie Hospital,
Manchester, M20 9BX, UK.
23 patients with intermediate prognosis small cell lung cancer
were treated with ifosfamide 5 g m 2, mesna 8 g m 2,
adriamycin 50 mgm-2, and etoposide 120 mgm-2 i.v. on
day 1, etoposide 120 mgm-2 i.v. on day 2 and a further
240mgm 2 of oral etoposide on day 3. A total of 6 courses
were given to each patient. In addition 8 patients with
limited stage disease were given mediastinal radiotherapy
following chemotherapy. The median age was 59 years, 10
patients having limited stage disease and 13 extensive stage
disease. So far 120 courses have been administered. Non
haematological toxicity has been mild consisting mainly of
nausea and vomiting. However, haematological toxicity has
resulted in 14 courses having to be delayed because of
myelosuppression, 10 patients experiencing > WHO grade 4
leucopenia.
To date there have been 8 complete responses and 11
partial responses giving an overall response rate of 83%. To
date 3 patients have died from lung cancer and there has
been one toxic death. 16 of these 19 responses were seen
after 3 courses. Treatment resulted in a marked improvement
of the Karnofsky performance score. Before treatment only 6
patients had a KP>80 as compared with 17 one month
following chemotherapy. There was a similar improvement in
the MRC respiratory score.
Carboplatin (C), Ifosfamide (I), Etoposide (E) with mid course
vincristine (V) and thoracic radiotherapy for limited stage
small cell lung cancer (SCLC)
M.J. Lind', H. Anderson', D.B. Smith', R. Stout2 &
N. Thatcher'
'CRC Department ofMedical Oncology; and 2Department of
Radiotherapy, Christie Hospital, Manchester, M20 9BX, UK.
Carboplatin has high single agent activity in SCLC but has
considerable myelosuppression. The I +E combination is
associated with only mild toxicity. Starting in September
1985, the three drugs were used in combination with V.
Thoracic radiotherapy either by a single rotation treatment
or 8F parallel pair was given at the end of chemotherapy
(CT). The regimen used was C-300mgm-2 i.v. day 1; I-
5gm-2 over 24h with mesna i.v. day 1; E-120mgm-2 i.v.
days 1, 2 and 240mgm-2 orally day 3, with mid course day
14, V-0.5mg i.v. The courses were repeated every 28 days for
a total of six. 42 patients have entered the study, the
metastases were pleural effusion 21%, nodes 19%,
mediastinum 62%, elevated alk.phosph. 29%, LDH 31%
and other liver enzymes 43%. So far 222 courses have been
given and 72% of patients have received all 6 courses. The
CR rate is 50%, PR 31% and 69% of all patients responded
by course two. The median survival is 13 months, range 1-
18+. Brain relapse as the solitary site has occurred in 19%
of patients. There were three treatment related deaths with
leucopenia and 7% of courses have been delayed because of
toxicity. Nadir counts were in the majority >grade 3 usually
occurring on week 3 after CT. Rapid improvement in the
Karnofsky score in 71% patients occurred with the CT
despite considerable myelosuppression. Prophylactic brain
irradiation may have been indicated for this group of
patients.
Carboplatin (Cp), VP16 (V) and ifosfamide (I) intensive
chemotherapy (CT) for small cell lung carcinoma (SCLC)
T.J. Perren, I.E. Smith, M.J. Plant & J.R. Yarnold
Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Cp+V has proved very active against SCLC (85% response)
but with short duration. A more intensive full dose 3 drug
combination of Cp 400mgm 2 i.v. day 1, V 100mgm -2 i.V.
day 1-3, and I 5 gm-2 day 1 (24h infusion) with mesna, q
28 days x 6 courses has therefore been used in 37 fit (ECOG
performance status 0-2) previously untreated SCLC patients.
Limited disease (LD) patients also received hyperfractionated
thoracic radiotherapy concurrently with the first 2 CT
courses (15Gy x 15 x 5 days x 2 courses). Prophylactic cranial
irradiation (PCI) was offered to all LD patients achieving
CR. 30 patients (19 males) are so far evaluable (>2 courses
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Patients CR PR Overall Response
LD 16 10 (63%) 5 15 (94%)
ED 14 3 (21%) 11 14 (100%)
For LD patients median survival has not been reached, 1
year actuarial survival is 85%; for ED patients median
survival is 8 months. 3 LD patients (19%) have had systemic
relapse, and 3 asymptomatic CT scan CNS relapse before
PCI; 9 ED patients (64%) have relapsed. Main toxicity was
myelosuppression: 72% patients required dose reduction, 7%
treatment delay, and 7% (2) had treatment deaths. Main
toxicity details are as follows:
WHO Grade
0 1-3 3-4
WBC suppression 0 0 30 (100%)
Platelet suppression 2 1 27 (90%)
Infection 8 10 (34%) 12 (40%)
Nausea/vomiting 0 15 (50%) 15 (50%)
Alopecia 0 0 30 (100%)
There was no significant, neuro-, nephro- or oto- toxicity.
This combination is feasible and highly active but causes
severe myelosuppression, and would only be of clinical value
in LD patients if good long term control can be achieved.
GR38032F in the control of ifosfamide induced nausea and
vomiting
J.A. Green, S.W. Watkin & P. Hammond
CRC Department ofRadiation Oncology, Clatterbridge
Hospital, Bebington, Merseyside, UK.
Ifosfamide (I) is one of the most active drugs in the
treatment of non-small cell lung cancer, and is also used in
the treatment of small cell lung cancer. One of the principal
side effects is prolonged WHO II or III nausea and vomiting
over 24-36h. GR38032F is a potent highly selective antago-
nist of 5HT3 receptors which is effective against drug
induced emesis in animals, and preliminary studies in pa-
tients have suggested antiemetic activity against cytotoxic
chemotherapy regimens. Six patients receiving ifosfamide at
a dose of 6.5-8 g as a 24 h infusion along with mesna 9-12g
over 36h were entered in the study. Four patients had
received no prior chemotherapy. GR38032F was given at a
dose of 4mg 15min before the start of the ifosfamide
infusion and for 6 further doses at 6 hourly intervals.
Response was assessed as the number of emetic episodes
(any vomit productive of liquid or 1-5 retches within a 5min
period) over the 48h after the start of I infusion. Two
patients had no nausea or vomiting in the study period, 2
patients experienced only one emetic episode, and the 2
patients who had received prior cytotoxic chemotherapy had
4 and 2 emetic episodes respectively. One further patient
treated with a dose of 8 mg every 6 h had no nausea,
retching or vomiting. No abnormality in haematological or
biochemical parameters were detected, and only one patient
experienced moderate drowsiness, which was considered to
be WHO Grade II CNS toxicity related to the I. It is
concluded that GR38032F is a safe and effective antiemetic
in the control of ifosfamide induced nausea and vomiting.
Randomised trial of planned versus as required chemotherapy
in small cell lung cancer (SCLC)
R. Souhamil, C. Ash1, S. Spiro2, D. Geddes3, J. Tobias1,
P. Harper4, H. Earl1 & L. James1
'Department ofClinical Oncology, University College and
Middlesex School ofMedicine, London, WCJ; 2Brompton
Hospital, London; 3London Chest Hospital, London; and
4Guy's Hospital, London, UK.
The poor prognosis of most patients with SCLC has led to
assessment of a variety of palliative approaches to chemo-
therapy. This trial assesses the value of using chemotherapy
according to the rate of progression of the disease in the
invididual patient.
Patients with both limited or extensive SCLC with poor
prognostic features (Souhami et al., Cancer Res. 45, 2878,
1985) have been entered into a randomised trial. In one
group chemotherapy (cyclophosphamide 1 gm-2 day 1,
vincristine 2mg day 1, etoposide 100mg bd days 1-3) is
given every 3 weeks for a total of 8 cycles. In the other
group patients receive the same chemotherapy only when
there is disease progression. Patients with responding or
stable disease who are asymptomatic are not treated but
are seen every 3 weeks and reassessed. 170 patients have been
randomised up to May 1987. In the 'as required' arm the
median treatment free interval between course 1 and 2 was
47 days; course 2 and 3: 46 days; course 3 and 4: 51 days;
course 4 and 5: 46 days. These intervals are over twice as
long as the 'planned' chemotherapy. So far there is no
difference in survival in the two arms. Quality of life assess-
ments ofthe two forms oftreatment are in progress. This trial
represents a new approach to palliative treatment of SCLC.
Treatment duration in small cell lung cancer (SCLC): A
randomised trial
R. Souhamil, H. Earl', C. Ash', S. Spiro2, D. Geddes3,
P. Harper4, J. Tobias' & H. Quinn'
'Department ofClinical Oncology, University College and
Middlesex School ofMedicine, London; WCJ, 2Brompton
Hospital, London; 3London Chest Hospital, London; and
4Guy's Hospital, London, UK.
616 patients with both limited and extensive SCLC were
entered into a randomised trial comparing two durations of
initial treatment and the value of chemotherapy on relapse.
Patients were staged by isotope bone scan and liver
ultrasound, and stratified according to extent (limited or
or extensive). Patients were then randomised to receive either
4 or 8 courses of chemotherapy (cyclophosphamide 1 gm-2
day 1, vincristine 2mg day 1, etoposide 100mg tds days 1-3)
3 weekly. At presentation patients were also randomised for
treatment at relapse, either to receive further chemotherapy
(doxorubicin 50mgm-2, and methotrexate 50mgm 2, every
3 weeks) or symptomatic treatment alone. 610 patients were
evaluable for response and survival.
Response to short (S) and long (L) initial chemotherapy
were similar (S=61%, L=63%), as were response rates to
relapse chemotherapy (S=25%, L=18%). Overall median
survival (MS) from course 1 was analyised by intention to
treat, and patients randomised to 8 courses of initial chemo-
therapy had a slightly longer MS than those randomised to 4
courses (MS, 39 vs. 32 weeks, P=0.085). Progression free
interval (PFI) after initial chemotherapy was longer in
patients receiving 8 rather than 4 courses (Median, 31 vs. 23
weeks, P=0.0002). Survival from relapse was longer for
patients receiving relapse chemotherapy than for those re-
ceiving symptomatic treatment alone (MS, 17 vs. 12 weeks,
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shorter relapse free interval with 4 cycles, and a worse
overall survival (MS, 42 vs. 52 weeks, P=0.02). This dif-
ference was not apparent if chemotherapy was given on
relapse. Short initial chemotherapy therefore gives worse
survival than long, unless relapse chemotherapy is given.
Surgical resection and adjuvant chemotherapy for limited stage
small cell carcinoma (SCLC)
S.W. Watkin', D. Kaplan2, J.A. Green1 & R.J. Donnelly2
1University ofLiverpool Department ofRadiation Oncology,
Clatterbridge Hospital, Bebington, Wirral, Merseyside, L63
4JY; and 2Regional Adult Cardiothoracic Unit, Broadgreen
Hospital, Thomas Drive, Liverpool 14, UK.
Between 1980-1986 33 patients, 21 male and 12 female, aged
41-72 years, mean 60.3 years underwent surgery for SCLC.
There were 15 lobectomies and 18 pneumonectomies. Pre-
operative diagnosis was SCLC in 13 (39%), NSCLC in 3
(9%) and in 6 the pre-operative biopsy was non-diagnostic.
Of the remainder biopsy was not possible in 6 (18%) and
there was insufficient data in 5 (15%). Post-operative his-
tology was SCLC in all cases and in one there were elements
of adenocarcinoma. Disease was confined to the lung in 17
cases and at thoracotomy 16 were found to be locally
advanced or have residual microscopic disease. Seventeen
patients received adjuvant chemotherapy and 3 also received
prophylactic cranial irradiation. 8/17 received chemotherapy
with 4 cycles of a combination chemotherapy regime
(CAV+IMVP-16). Seven patients are alive at 6-53 months
of whom 4 have not relapsed and there have been 17 deaths,
none of which were related to chemotherapy. There were 3
early post-operative deaths and there is incomplete follow-up
in 9. Median survival of the 24 patients with complete data
is 14 months, 1 year survival 55% and 2 year survival 22%.
These results suggest that surgery is an effective form of
treatment for selected patients with limited stage SCLC when
combined with intensive adjuvant chemotherapy.
High dose chemotherapy with autologous bone marrow rescue
in small cell lung cancer
C. Wilson, D. Pickering, S. Stewart, K. Vallis, H. Kalofonos,
A. Cross, D. Snook, J. Goldman, C.G. McKenzie &
A. A. Epenetos
Departments ofClinical Oncology and Haematology,
Hammersmith Hospital, London, UK.
Twenty five consecutive patients diagnosed as having small
cell lung cancer (SCLC) were treated with etoposide and cis-
platinum. After assessment for tumour response, autologous
bone marrow (ABM) was collected from 5 patients in good
clinical state who had shown a partial response (PR) and no
marrow involvement with tumour. These patients were
treated with high dose cis-platinum, etoposide and mel-
phalan and then by ABM infusion. Although all patients
(3 with extensive and 2 with limited disease) achieved com-
plete remission (CR), 3 patients with extensive disease
relapsed and died of their disease. One patient with limited
disease died of infection while pancytopenic; postmortem
examination in this patient showed the presence of tumour.
One patient who achieved CR, received local chest irradia-
tion and continues in remission. Although patient numbers
are small, our data support the conclusion that high dose
chemotherapy and autologous bone marrow rescue has a
very small role if any, in the management of patients with
extensive or limited stage SCLC.
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